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Development Of A Gene Therapy For Muscular Dystrophy And The Broader
Implications Of Immune Responses To Vector Encoded Antigens
Abstract
Duchenne Muscular Dystrophy (DMD) is a devastating progressive muscle wasting disorder caused by
mutations on the DMD gene that result in the complete absence of its protein product, dystrophin. Studies
involving Adeno-associated viral (AAV) vector-mediated gene transfer approaches highlight the
challenges the immune system can impose when it encounters “non-self” dystrophin epitopes. As an
alternative, our lab relies on utrophin, a dystrophin paralog that retains most of dystrophin’s structural and
binding elements. Importantly, normal thymic expression in DMD subjects should protect utrophin by
central immunologic tolerance. Here I describe how an AAV vector containing a codon optimized
truncated utrophin transgene (AAV-μUtrophin) is a highly functional, non-immunogenic substitute for
dystrophin, preventing the most deleterious histological and physiological aspects of muscular dystrophy
in small and large animal models of DMD. Following systemic administration of AAV-μUtrophin in
neonatal dystrophin-deficient mdx mice, histological and biochemical markers of myonecrosis and
regeneration are completely suppressed throughout growth to adult weight. In the dystrophin-deficient
golden retriever model, μUtrophin non-toxically prevented myonecrosis, even in the most powerful
muscles. In a stringent test of immunogenicity, focal expression of μUtrophin in the deletional-null
German shorthaired pointer canine model produced no evidence of cell-mediated immunity, in contrast to
the robust T cell response against similarly constructed μDystrophin. These findings support a model in
which utrophin-derived therapies might be used to treat clinical dystrophin deficiency, with a favorable
immunologic profile. Our latter immunological findings would become the biological premise for a
prospective vaccine against SARS-CoV-2 virus, the agent responsible for the ongoing global COVID-19
pandemic. SARS-CoV-2 relies on its major surface antigen, Spike protein, to gain access into host cells
and therefore is a key target for vaccines. A single intramuscular injection in adult C57Bl/6 mice of a
synthetic Spike protein (M8B), driven by a CMV promoter and packaged in an AAV vector (AAV-CMVM8B), resulted in transient expression and a robust cell mediated immune response against M8B.
Together these findings demonstrate how an AAV-mediated gene transfer approach can be used to
provide a therapeutic effect and can be tuned to drive or steer away an immune response against vector
encoded antigens.
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ABSTRACT

DEVELOPMENT OF A GENE THERAPY FOR MUSCULAR DYSTROPHY AND THE
BROADER IMPLICATIONS OF IMMUNE RESPONSES TO VECTOR ENCODED ANTIGENS
Leon Morales
Hansell H. Stedman and Jean Bennett

Duchenne Muscular Dystrophy (DMD) is a devastating progressive muscle wasting disorder
caused by mutations on the DMD gene that result in the complete absence of its protein product,
dystrophin. Studies involving Adeno-associated viral (AAV) vector-mediated gene transfer
approaches highlight the challenges the immune system can impose when it encounters “non-self”
dystrophin epitopes. As an alternative, our lab relies on utrophin, a dystrophin paralog that retains
most of dystrophin’s structural and binding elements. Importantly, normal thymic expression in
DMD subjects should protect utrophin by central immunologic tolerance. Here I describe how an
AAV vector containing a codon optimized truncated utrophin transgene (AAV-μUtrophin) is a highly
functional, non-immunogenic substitute for dystrophin, preventing the most deleterious histological
and physiological aspects of muscular dystrophy in small and large animal models of DMD.
Following systemic administration of AAV-μUtrophin in neonatal dystrophin-deficient mdx mice,
histological and biochemical markers of myonecrosis and regeneration are completely suppressed
throughout growth to adult weight. In the dystrophin-deficient golden retriever model, μUtrophin
non-toxically prevented myonecrosis, even in the most powerful muscles. In a stringent test of
immunogenicity, focal expression of μUtrophin in the deletional-null German shorthaired pointer
canine model produced no evidence of cell-mediated immunity, in contrast to the robust T cell
response against similarly constructed μDystrophin. These findings support a model in which
utrophin-derived therapies might be used to treat clinical dystrophin deficiency, with a favorable
immunologic profile. Our latter immunological findings would become the biological premise for a
prospective vaccine against SARS-CoV-2 virus, the agent responsible for the ongoing global
COVID-19 pandemic. SARS-CoV-2 relies on its major surface antigen, Spike protein, to gain
access into host cells and therefore is a key target for vaccines. A single intramuscular injection in
adult C57Bl/6 mice of a synthetic Spike protein (M8B), driven by a CMV promoter and packaged in
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an AAV vector (AAV-CMV-M8B), resulted in transient expression and a robust cell mediated
immune response against M8B. Together these findings demonstrate how an AAV-mediated gene
transfer approach can be used to provide a therapeutic effect and can be tuned to drive or steer
away an immune response against vector encoded antigens.
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INTRODUCTION

Clinical description
Duchenne Muscular Dystrophy (DMD) is an X-linked disorder characterized by progressive muscle
weakness and wasting affecting approximately 1 in every 5000 live male births (PPMD.org). DMDlike symptoms have been described in the literature as far back as the year 1850 (Drouin et al,
2014), but the disease got its name from the French physician Duchenne de Boulogne. On average
boys are diagnosed by the age of four, become wheelchair bound in their late teens, and suffer a
premature

mortality

due

to

cardiorespiratory failure.

Current

standard

care

involves

glucocorticosteroids which can minimize inflammation and delay fibrosis (McDonald, C.M., et al.
2013 A). Advances in mechano-ventilatory intervention have been effective at increasing life
expectancy,

however

these

improvements

have

uncovered

the

slower

progressing

cardiomyopathies, which now have emerged as the next most common cause of mortality (Eagle
et al. 2007). With recent improvements in palliative care and intervention, average life expectancy
for DMD patients has extended into the early thirties. Although the clinical course has been well
described, there is currently no approved treatment and large gaps in our understanding of the
pathogenesis leading to disease still remain.

Molecular deficiency
DMD is caused by mutations on the DMD gene that eliminates the expression of the essential 427
kDa protein product, dystrophin (Hoffman et al, 1987). The DMD gene is one of the largest in the
human genome, encompassing 2.4 million base pairs of DNA and made up of 79 exons (Koenig,
et al. 1987). Its extreme size is thought to contribute to the high incidence of de-novo mutations.
The vast majority of mutations within the DMD gene are large multi-exon indels that in turn disrupt
the downstream reading frame, while the remaining are composed of single point mutations or
small frameshift rearrangements (Prior et al. 2005). Becker Muscular Dystrophy (BMD) is a milder
form of DMD and is caused by in-frame mutations that result in a reduction in the amount or
alteration in the size of dystrophin.
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Pathogenesis and Pathophysiology
Dystrophin is a cytoskeletal rod-shape protein whose length is mostly composed of 24 spectrin-like
repeats interdigitated by 4 hinge regions (Koenig et al. 1988). Spectrin repeats 16/17 contain a
neuronal Nitric Oxide Synthase (nNOS) binding site that allows nNOS to be localized to the
sarcolemma. At its N-terminus, an F-actin domain binds at the costamere. At the C-terminus, a
cysteine-rich domain plays an important role of nucleating the assembly of a multi-protein complex
known as the dystrophin associated protein complex (DAPC) at the sarcolemma. Based on this
architecture (Figure 1), dystrophin plays the mechanical role of transmitting the forces generated
during contraction across the muscle cell out into the extracellular matrix. In the absence of
dystrophin there is a reduction of the DAPC components, which in turn renders the muscle cell
more susceptible to contraction-induced sarcolemmal injury (Petrof et al. 1993). Tears in the
sarcolemma allow the cytoplasmic muscle enzyme creatine kinase (CK) to leak into the serum and
reach levels that are hundreds of times greater than in healthy controls, thus serving as an
important biomarker. Normally, levels of free calcium inside the cell are kept low, but with
membrane injury, calcium has unregulated access. Persistent increased levels of intracellular
calcium result in hyper-contraction and activation of necrotic signaling pathways. Cell debris is
cleared out by mononuclear cells and replaced with fibrosis and fat.

The DMD gene encodes various dystrophin isoforms ranging in molecular weights. The main
isoform found in striated muscle is the full length isoform at 427 kDA. Shorter isoforms can also be
found in smooth muscle, kidney and the nervous system where dystrophin’s role remains less clear.
In smooth muscle, dystrophin is thought to regulate phenotypic maturation of airway smooth muscle
(Sharma et al. 2014). Involvement of smooth muscles within the gastrointestinal tract and urinary
tracts manifest late and are less frequent. Symptoms include slow and uncoordinated movements
leading to dysphagia, constipation and diarrhea (Boland et al. 1996).

Dystrophin and utrophin’s role in mediating the proper assembly of the DAPC is also important in
non-muscle tissue (Haenggi et al. 2006). In the central nervous system, the DAPC is thought to
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play an important role in brain development, synapse formation and plasticity (Rosman et al. 1966)
(Chamberlain et al. 1988) (Felisari et al. 2000) (Mehler et al. 2000) (Moizard et al 1998) (Moizard
et al. 2000). Behavioral studies have shown that about one third of DMD patients may have a
variable degree of cognitive impairment and a lower IQ (Bresolin et al. 1994) (Anderson et al. 2002).

Figure 1. Graphical representation of DMD gene and dystrophin protein.
Dystrophin is located in a region known as the cortical cytoskeleton, depicted here
in yellow. Dystrophin’s N-terminal contains an actin-binding domain that interacts
with F-actin, while at the C-terminal end a Cysteine rich region interacts with the
Dystrophin associated protein complex (DAPC) at the sarcolemma. A rod domain
composed of 24 spectrin-like repeats makes up most of dystrophin’s length.
Spectrin repeats 16/17 contain a neuronal Nitric Oxide Synthase (nNOS) binding
site. Graphics were adapted from Baresssi et. al, 2006. Prior et. al, 2005.
Blausen.com, "Medical gallery of Blausen Medical 2014".

Approaches and Risks
DMD’s complex pathophysiology and high disease burden has prompted investigators to develop
potential therapies aimed at a wide range of molecular and cellular targets. Myoblast
transplantation has given disappointing results due to a lack of cell survival, immune rejection and
limited dispersal through tissue barriers (Mouly et al. 2005) (Mendell et al. 1995). More promising
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leads have included exon skipping and stop codon read-through, however these approaches have
to be administered frequently, can only be offered to a limited number of patients with a specific
genetic mutation, and at best offer marginal benefits (Opar et al. 2012).

Dystrophin gene replacement was immediately proposed after the since the discovery of the DMD
gene. The earliest attempts involved simple intramuscular injection of plasmid DNA but proved to
be an inefficient method to achieve expression (Duan et al. 2008). Vector based approaches relied
on recombinant human adenoviruses to achieve gene transfer of full-length dystrophin (Clemens
et al. 1996) (DelloRusso et al. 2002) (Haeker et al. 1996). The discovery of an individual missing
46% of dystrophin (exons 17-48) who at 61 years of age was still walking with the aid of a stick,
shifted the notion that only a full-length dystrophin is required (England et al. 1990). This finding
suggested that perhaps the rod domain was more dispensable compared to other domains. It also
emphasized the importance of retaining strength in dystrophin’s rod domain and informed the
design of future “mini” dystrophin constructs. Shortly after, studies involved the use of internally
deleted dystrophin using adenoviruses (Ragot et al. 1993), however this approach was quickly
abandoned due to the immunogenicity and limited biodistribution of the adenovirus envelope.

Adeno-associated viral (AAV) vector-mediated gene transfer has more recently emerged as the
vector of choice for muscle disorders due to the existence of several muscle-tropic serotypes that
can achieve whole-body transduction (Gregorevic et al. 2004), the inherent capacity for persistent
transgene expression in post-mitotic cells (Podsakoff G. et al. 1994), and that it does not
cause any human disease. AAV was first discovered as a contaminant in an adenoviral prep
(Atchison et al. 1965). However, the large size of dystrophin cDNA (14 kb) exceeds the relatively
small AAV DNA packaging capacity (~5kb). Nonetheless AAV encoding truncated versions of
dystrophin has been shown to provide therapeutic benefit in mdx mice (Wang et al. 2000)
(Gregorevic et al. 2006) and dogs (Le Guiner et al. 2017). However, in an ensuing Phase I clinical
trial, using a local gene transfer approach, there was evidence for a cell-mediated immune
response directed against the dystrophin-derived transgene product (Mendell et al. 2010).
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Meanwhile, systemic AAV mediated deliver of micro dystrophin in a neonatal dystrophic dog
resulted in weight loss and clinical signs of inflammatory myopathy (Kornegay et al. 2010). These
and other studies (Moore et al. 2010) serve as cautionary examples for the potential of unwanted
autoimmune responses against cells expressing “non-self” dystrophin epitopes and therefore
warrant alternative strategies.

Indeed, favorable results using a systemic gene therapy approach for treatment of spinal muscular
atrophy 1 (SMA-1) suggests that this approach can be tolerated, safe and effective for treating a
neuromuscular disease (NCT02122952) (Mendell et al. 2017). Meanwhile, in the Audentes
Therapeutics ASPIRO gene therapy trial, systemic gene therapy for the treatment of X-linked
myotubular myopathy (XLMTM) revealed a spectacular therapeutic response at the low dose
(NCT03199469). High-dose systemic AAV delivery has also been used to treat hemophilia A with
no signs of SAEs (Rangarajan et. al, 2017).

Utrophin
The Stedman lab has focused on an alternative approach that relies on dystrophin’s paralog
protein, utrophin. Utrophin diverged following a gene duplication early in vertebrate evolution and
shares a considerable amount of dystrophin’s structure, function and sequence, including critical
binding domains located near the N- and C-terminus (Love DR et al. 1989) (Tinsley et al. 1992)
(Figure 2). Utrophin has 22 spectrin repeats and is missing an nNOS binding site. Despite the high
prevalence of mutations in DMD that eliminate dystrophin expression, utrophin thymic expression
during in-utero development (Mesnard-Rouiller et al. 2004) and persistent expression at the
myotendinous and neuro-muscular junction should be sufficient to establish central tolerance.
Indeed, investigators have shown that full length and truncated versions of utrophin can
compensate for the lack of dystrophin and provide measurable levels of phenotypic rescue in
murine models for DMD (Tinsley et al. 1998) (Gilbert et al. 1999) (Odom et al. 2008). Upregulation
of endogenous utrophin has been actively pursued as a potential therapy, but generates at best,
sub-protective levels of utrophin (Moorwood et al. 2011) (Khurana et al. 2003).
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μUtrophin
Crystal structures of a spectrin-like repeat from dystrophin and utrophin suggest that amino acid
side-chain interactions between adjacent repeats create an interlocking interface critical to the
strength of the rod (Muthu et al. 2012). This principle may explain the phenotypes resulting from
in-frame deletions and duplications in BMD patients, since most disruptions of the triple helical
repeats have the potential to focally weaken the rod domain. To minimize the risk of creating a
‘weakest link’, we focused on deletions flanking hinge 2, and also deleted C-terminal sequences
beyond the approximate end of the ZZ domain (Ishikawa et al. 2004. Hnia et al. 2007). In light of
these considerations, we synthesized a transgene based on wild type utrophin mRNA sequences,
and then improved expression by optimizing to the codon bias of mRNAs for the most abundant
proteins of muscle: myosin and actin, all while being driven by a constitutive CMV promoter. We
call this synthetic transgene product μUtrophin (Figure 2). μUtrophin is 22–27% divergent from
the three constructs being used in clinical trials (Foster et al. 2008) (Odom et al. 2008)
(Sonnemann et al. 2009), reflecting differences in alignment, codon bias and primary protein
structure. μUtrophin most closely resembles Sarepta’s delta R4–R23 (NCT02376816). Pfizer
(NCT03362502) is using a 5 spectrin repeat ‘delta R3–R21’repeat and Solid is using a 5 repeat
‘delta R2–R15, R18-22.’, μUtrophin lacks an nNOS binding site, like two of the three transgenes
selected for early clinical trials. A common features of all these constructs is the presence of the
N-terminal domain, the cysteine-rich domain, spectrin-like repeats 1 and 24, hinges 1 and 4, as
well as the absence of the C-terminal domain. Solid Biosciences and Pfizer are using an AAV9
capsid, while Sarepta is using an AAV-rh74 (similar to AAV8) and all three trials are using a
muscle specific promoter.
ClinicalTrials.gov reference numbers:
NCT03362502 (Pfizer-AAV9.hMSP.PF-06939926)
NCT02376816 (Sarepta- rAAVrh74.MCK.micro-Dystrophin)
NCT03368742 (Solid Therapeutics-AAV9.hMSP.SGT-001)
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Figure 2. Rationale for a Utrophin gene therapy-based approach. Utrophin
arose from an ancestral duplication (*) and shares many of dystrophin’s structural
and binding domains. A DMD patient’s thymus will express all utrophin epitopes
but fail to express any epitopes within dystrophin’s deleted region. μUtrophin
includes spectrin-like repeats 1-3 and 22, was codon optimized for expression in
striated muscle and is driven by a CMV promoter.
Animal Models
A large number of animal models have been well characterized and are available to further our
understanding of the pathological consequences of dystrophin deficiency and to test potential
therapies for treating DMD. Currently there are at least 60 different animal models for DMD, both
naturally occurring, and laboratory derived (McGreevy et al. 2015). It’s important to emphasize the
genetic differences between DMD patients and the animal models because it will dictate the
questions we and other groups can reliably address in the model.

The most widely used animal for DMD research is the mdx mouse. It was first discovered in a
colony of C57BL/10ScSn mice that showed elevated levels of serum creatine kinase and
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histological evidence of myopathy (Bulfield et al. 1984). A nonsense point mutation in DMD’s exon
23 creates a premature stop codon, which eliminates the expression of dystrophin (Sicinski et al.
1989). Despite being dystrophin deficient, mdx mice have a relatively mild phenotype with a ~25%
reduction in life span (Chamberlain et al. 2007). This milder phenotype is thought to be partially
due to upregulation of the compensatory protein, Utrophin (Deconinck A.E., et al. 1997). In addition,
pronounced regeneration in mice is able to compensate for muscle fiber necrosis without net loss
of aggregate myofiber mass (Carnwath et al. 1987) (Muntoni et al. 1993) (Pastoret et al. 1995). In
the first couple of weeks of life, mdx mice muscles are indistinguishable from those of their
C57/10ScSn counterpart. However, after 3-6 weeks of age, mdx muscle tissue begins to
breakdown and undergo a series of cycles of degeneration and regeneration. Histological findings
are presence of centrally nucleated muscle fibers, mononuclear cell infiltration, and fibrosis. Despite
this ongoing regenerative process, the majority of skeletal muscle remains stable, with the
exception of the diaphragm, which shows progressive deterioration (Stedman et al. 1991).

The Golden Retriever Muscular Dystrophy (GRMD) is the first and best-characterized large canine
model of DMD. The GRMD arose from a single base change in dystrophin’s intron 6 acceptor splice
site that results in a frame shift of the transcript, while leaving the entire dystrophin coding sequence
intact (Sharp et al. 1992). Muscle from GRMD dogs have been found to express detectable
amounts of near-full length dystrophin by means of alternative exon splicing (Schatzberg et al.
1998). As a result of this process, the GRMD model can fail to expose some of the immunological
consequences from dystrophin-based treatments. However, its severe phenotype, defined natural
history, and a physiology that more closely resembles humans, makes it a key model when
assessing efficacy. Limb weakness and exercise intolerance starts around 2 to 3 months of age
(~3 years of age in humans) (Valentine et al. 1988). Muscle atrophy, joint contracture,
hypersalivation, dysphagia, abnormal gait and signs of cardiac involvement become apparent at
~6 months (Fan et al. 2014) (Fine et al. 2011) (Valentine et al. 1989). One of the earliest and most
affected muscles are the powerful masticatory muscles like the temporalis, thought to be partly
responsible for the excessive sialorrhea and difficulties chewing and swallowing. Death often
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occurs around 3 years of age (~75% reduction of lifespan). Similar to humans with DMD, GRMD
have histological lesions and fewer myofibers containing central nucleation, along with elevated
serum levels of CK (Cozzi et al. 2001).

The German shorthaired pointer-muscular dystrophy (GSHPMD) is a recently described, naturally
occurring canine model of DMD. In Olby et al, 2010, the clinical description of 2 male GSHPMD
siblings involved poor growth, muscle atrophy, pelvic limb weakness, and episodes of coughing.
The deletion spans 5.6 Mb of the X chromosome and encompasses all coding exons of the DMD
gene (VanBelzen et al. 2017). Since the GSHPMD lacks the entire DMD gene it is therefore void
of any possible level of immunological tolerance or sensitivity to wild-type dystrophin epitopes, thus
providing a superior platform for the prediction of immune responses to gene therapies for DMD.
Despite being dystrophin deletional-null, the GSHPMD’s clinical progression is milder compared to
the GRMD canine model, involving mechanisms yet not well understood.
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CHAPTER 1: SUITE OF CLINICALLY RELEVANT FUNCTIONAL ASSAYS IN MICE

INTRODUCTION
Although the mdx mouse has been the most utilized animal model in preclinical development
relevant to muscular dystrophy, challenges remain in developing assays that focus on the same
features of disease pathogenesis that are the subject of existing clinically relevant tests. A major
limitation of some of the current preclinical assays is their invasive nature; either in-vivo assays
like in the case of non-volitional exercise or electrically stimulated muscle contraction, or ex-vivo
assays which require euthanizing the animal (Aartsma et al. 2014) (Kobayashi et al. 2008)
(Nelson CE et al. 2016) (Xu L et al. 2016). Developing noninvasive volitional assays has been
historically challenging when using the mdx mouse because of its mild phenotype. This mild
phenotype is attributed to upregulation of the compensatory utrophin protein, and the robust
regeneration of skeletal muscle in mdx mice compared to DMD patients (Deconinck AE et al.
1997).

The 6-minute walk distance (6MWD) test is uniquely sensitive to strength and endurance and
represents the optimal primary end point for therapeutic development in DMD patients that can still
walk (McDonald CM. et al. 2013). A drawback to such clinical tests is that the effect size tends to
be small in DMD boys where extreme phenotypic variability can be seen in the rate of progression
with age. However, the mdx mouse tends to show a larger effect size. Prior reports show that both
wild and captive mice exhibit a natural and partially heritable inclination to run in a wheel (Meijer et
al. 2014. Sherwin et al. 1998). In an effort to develop an assay that more closely resembles the
6MWD, I chose to revisit and optimize the use of an open field tracking system with an
accompanying running wheel, with the hope of accelerating translation of experimental
therapeutics, while providing a novel opportunity for mechanistic dissection. I studied c57Bl (c57)
and mdx mice, which are on the same background strain.
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RESULTS

Locomotor performance with open field and running wheel
The open field cage is widely used without a running wheel to comprehensively assess locomotor
and behavioral activity of murine models for other neurological diseases (Tatem et al. 2014). I first
present an overview showing the granularity of the data collected by the open field system, which
highlights the dramatic difference in wheel pattern activity by c57 wild-type and mdx mice (Figure
3A). Both c57 and mdx mice chose to achieve the vast majority of their total distance in the wheels
instead of the cages (Figure 3B). When the distance in the cage alone was examined, no difference
was seen with the exception of a single mdx outlier mouse that exhibited unusually high exploratory
locomotor behavior followed by death the next day (Figure 3C). Presumably related to over-exertion
the preceding day. However, it was the distance traveled in the running wheels that accounted for
the biologically significant locomotor difference between c57 and mdx mice (Figure 3D). Despite
the difference in ages of the mice used for locomotor testing, we observed no significant difference
in locomotor activity that was attributable to age (Figure 3E). Although analysis of total distance
traveled showed a statistically significant difference between c57 and mdx mice, it is essential to
highlight the impact of potential variation between separate litters (Figure 3F).

Despite this large difference in distance covered in the wheels, c57 and mdx mice show similar
locomotor behavior in terms of their wheel-episode count (number of times they enter and exit the
wheels) (Figure 4A) and their rest time (Figure 4B). Upon analysis of the average individual wheelepisode counts for each mouse, we found a pronounced increase in the amount of time spent in
the wheel per episode for the c57 mice compared with the mdx (Figure 5A). Furthermore, the
distance covered by the c57 mice was significantly greater than the distance covered by the mdx
mice per wheel-episode (Figure 5B). The average velocity in the wheel of c57 mice was significantly
greater compared with mdx mice (Figure 5C). Thus, both c57 and mdx mice show similar levels of
exploratory behavior and modulate the speed and duration of their in-wheel exertion so as to
achieve the need for similar levels of post exertional rest. To determine if access to a running wheel
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had an impact on behavioral activity patterns in both c57 and mdx mice, we analyzed the following
parameters: stereotypic activity, grooming, ambulatory activity, and counterclockwise revolutions
in the cages (Table 1). Overall, access to the wheel does not appear to have a behavioral impact
on either c57 or mdx.

Figure 3. Overview of locomotor activity in the open field with accompanying
running wheel. A, Representative velocity plotter shows locomotor activity in the
running wheel for c57 and mdx mice over the 23-hour experiment. y-axis: running
velocity in the wheel, x-axis: time. B, both c57 (n=8; 97.9% of total distance) and
mdx (n=13; 89.1% of total distance) mice displayed a higher percentage of
distance traveled in the running wheel compared with distance traveled in the
cage. C, quantification of distance traveled in the cage by c57 mice (n=8) and mdx
mice (n=13). D, quantification of distance traveled in the wheel during the 23-hour
experiment in both c57 (n=8) and mdx mice (n=13). E, wheel running distance by
age of c57 (n=8) and mdx (n=13). F, quantification of the total distance traveled
with access to running wheel, c57 (n=6) and mdx (n=9) mice. Same color and
shape indicate mice from the same litter.
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Figure 4. Comparison of wheel episode count and rest time over 23-hour
access to the running wheel. A, Quantification of wheel episode count B, and
rest time between c57 (n=8) and mdx( n=13) mice.

Figure 5. Comparison of locomotor parameters in the running wheel between
c57 and mdx mice. A, Quantification of time in running wheel B, distance traveled,
C, and running wheel velocity for each wheel episode between c57 (n=8) and mdx
(n=13) mice over the 23-hour experiment duration.

Table 1. Quantitative behavioral activities in c57 and mdx mice with and
without access to running wheel. Stereotypic and ambulatory activity are
quantified as the number of open-field cage system beam breaks resulting from
stereotypic behavior (grooming, head bobbing, etc.) and ambulation (horizontal
movement), respectively. Values are means ± SD. P < 0.05 is considered a
significant difference.
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Locomotor performance correlates with serum creatine kinase (CK)
As serum CK activity reflects the extent of sarcolemmal injury and is a biomarker used for identifying
and distinguishing wild-type from dystrophic mice (Figure 6A), we asked if innate behavioral
mechanisms exist to limit levels of in-wheel exertion below the threshold required for an acute
increase of this biomarker. We were surprised to not only see maintenance of serum CK values for
c57 mice, but a drop in serum CK values for mdx mice following the running wheel experiment
(Figure 6B), indicating that volitional in-wheel exertion does not result in acute injury. Furthermore,
there was a negative correlation between levels of serum CK serum and running wheel distance
(Figure 6C). However, serum CK values collected after the whole limb force test were significantly
elevated for mdx mice compared with baseline values, whereas no difference was seen in c57 mice
values (Figure 6D).

Figure 6. Effect of wheel running on serum CK between c57 and mdx mouse.
A, quantification serum CK levels in c57 (n = 7) and mdx mice (n = 12) at 6 weeks.
B, Serum CK levels between c57 (n = 3) and mdx mice (n = 5) before and after
exposure to the running wheel. C, serum CK levels of c57 (n=7) and mdx (n=5)
mice and total distance traveled over the 23-hour access to the running wheel. D,
comparison of serum CK levels between c57 (n = 7) and mdx (n = 4) mice before
and after the whole limb force test.
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Effect of the whole limb force test on behavior locomotor activity
To further explore the ability of both c57 and mdx mice to limit their volitional exertion to prevent
injury, we decided to revisit and optimize the most commonly used in-vivo test for monitoring
impaired limb strength: the whole limb force test (Figure 7A). Following a total of seven pulls there
was a drop in force for both c57 and mdx mice over the course of the assay; however, the force
values declined at a more rapid rate in mdx mice (Table 2). At the end of the whole limb force test
it was surprising to observe a dramatic drop in subsequent spontaneous activity in the mdx mice
compared with their c57 counterparts (Figure 7B). To quantify this observation, we took advantage
of the open field activity plotter and found that the vertical activity 5 min prior (Pre) to the wholebody force test in c57 mice is indistinguishable from mdx mice (Figure 7C). However, there is a
significant, 17.4-fold drop in vertical activity in mdx mice compared with c57 mice for 5 and 10 min
immediately following the whole limb force test (3.5 ± 2.2 vs. 60.9 ± 12.1 units of activity,
respectively; effect size 1.99) (Figure 7D). Continued monitoring of the vertical activity for 1 hour
following the whole limb force test showed that the c57 mice were able to maintain some level of
vertical activity, whereas mdx mice exhibited minimal vertical activity (Figure 7E). Moreover, the
cumulative vertical activity of c57 and mdx mice during the 1 hour period post-whole limb force test
revealed a statistically significant difference (Figure 7F,G). Taken together, this hybrid test is able
to link a force grip test with the volitional aspect of measuring locomotor activity.

Table 2. Whole limb force test in c57 and mdx mice. Mice were pulled a total of
7 times and the subsequent force generated was tabulated. P < 0.05 is considered
as a significant difference.
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Figure 7. Hybrid test: Synergistic effect of the whole limb force test on
vertical activity.
A, Whole limb grip force grip test involves a series of 7 pulls and then both c57
and mdx mice are placed in an open field cage system. B, Locomotor activity of
both c57 and mdx mice 5 min Pre-whole limb force test, as well as the first 5
minutes and the second 5 minutes Post-force test. Lines represent horizontal
activity, and dots represent vertical activity. C, quantification of vertical activity in
the open field cage between c57 (n=11) and mdx mice (n=12) before the whole
limb force test showed no significant difference between c57 and mdx mice. D,
quantification of vertical activity 5 & 10 min after the force test (c57 n=11; mdx
n=12). E, quantification of vertical activity in 5-min intervals over the course of 1
hour Post-force test. F, analysis of cumulative post-vertical activity for 1 hour Postforce test and G, subsequent quantification (c57 n=5; mdx n = 8).
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Morphological changes in response to the whole limb force test
Observations of hematoxylin and eosin (H&E) stained mdx muscle specimens from the
gastrocnemius muscle (GM) demonstrate pathological alterations occur in both mdx mice with and
without the whole limb force test, including marked variation in fiber size, many centrally located
nuclei, hypercontracted fibers, and fibrosis (Figure 8A and C). There are no signs of an increased
number of degenerating muscle fibers despite the drop in activity observed post- whole limb force
test (Figure 8B and D).

Figure 8. Morphological changes in response to the whole limb force test.
Gastrocnemius muscle tissue section from mdx mice with (A and B) and without
(C and D) whole limb force test. H&E staining (A and C). These muscle sections
exhibit marked variation in fiber size, many centrally located nuclei (black arrows),
hypercontracted fibers (asterisks), and fatty connective tissue (black arrowheads).
Merged images (B and D) are stained for laminin (green), Evans blue dye (red),
DAPI (blue) show that degenerating muscle fibers (red) are present at the same
level in mdx mice both with and without the whole limb force test. Bar, 100 μm.
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Evaluation of respiratory rate in response to the whole limb force test
To investigate the mechanism behind the loss in vertical activity post-whole limb force test, we
conducted a series of noninvasive experiments in which the respiratory rate of both c57 and mdx
mice was measured. The results show no statistically significant difference in the respiratory rate
over the course of the whole limb force test for either c57 or mdx mice (Figure 9), despite the
dramatically reduced vertical activity in mdx mice.

Figure 9. Respiratory rate in response to the whole limb force test.
Quantification of respiratory rate after each series of force grip pulls. No significant
difference observed between c57 and mdx mice (n = 8).
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DISCUSSION
The most commonly used clinical tests in DMD encompass strength, but only the 6MWD measures
endurance as well (McDonald CM et al. 2013b). Development of preclinical assays with the
characteristics of the 6MWD can help accelerate translation of experimental therapeutics, while
providing novel opportunities for mechanistic dissection. The level of precision of the open field
cage system enabled us to find that the frequency of wheel running episodes and rest time were
indistinguishable between mdx and c57 mice (Figure 4). This observation suggests that mdx mice
behavior is impacted by the same motivational inputs that regulate the behavior in c57 mice, an
observation consistent with previous studies of informative, nondystrophic murine models
(Alekseev et al. 2010) (Meijer et al. 2014) (Momken et al. 2005). However, the time spent, the
average speed, and the interval distance covered during each wheel episode were greatly reduced
in mdx mice (Figure 5). Therefore, the results support the alternative interpretation that the
reduction in the running wheel distance is due primarily to the reduced capability to run, not a
decreased motivation to initiate this activity.

The fact that the mdx mice run at a lower average speed and for a shorter period of time before
“bailing out” suggests that one or more antalgic stimuli may be modifying behavior in such a way
as to avoid self-injury. To determine if wheel running had any detrimental effects on the mice, we
decided to look at serum creatine kinase (CK), an important biomarker for diagnosis, disease
progression assessment, and response to various therapeutic approaches in DMD (Glebsy et al.
1988) (Hathout et al. 2016) (TInsely et al. 1996). It was surprising to not only see stable levels of
serum CK values over the course of the experiment for c57 mice, but a drop in serum CK values
for mdx mice after wheel running (Figure 6B). We decided to take advantage of the previously
collected locomotor data and found a negative correlation between serum CK levels and the
running wheel distance. These data suggest a potential beneficial effect of the voluntary running
wheel for mdx, perhaps reflecting the elimination of inertial and/or gravitational load and the
animals’ use of motor unit recruitment patterns that largely avoid eccentric contraction (DupontVersteegden et al. 1994) (Hayes et al.1996).
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To gain a better understanding of both strength and endurance in mdx mice I decided to revisit the
most commonly used in-vivo test for monitoring impaired limb strength caused by disease
progression in mdx mice, the whole limb force test (De Luca et al. 2008). I was surprised to observe
an immediate and dramatic reduction of spontaneous activity in mdx mice following as few as two
force measurements. To quantify this observation, I relied on the open field technology, and found
that the vertical activity in c57 mice was indistinguishable from mdx mice before the whole limb
force test (Figure 7B, C). Following a total of seven pulls, there was a modest drop in force for both
c57 and mdx mice over the course of the assay, whereas the force values measured for the mdx
mice declined at a slightly more rapid rate (Table 2). However, a dramatic drop in spontaneous
vertical activity was observed in mdx mice following the whole limb force test (Figure 7D-G). As
described in my lab notebook, ”mdx mice appeared wiped out and fatigued post force test.” It’s
thought that the antalgic signals in a volitional test that serve to protect muscles, are overridden
during the nonvolitional component of the whole limb force test in mdx mice. As a result, additional
protective mechanisms come into play that subsequently reduce the level of spontaneous activity
disproportionate to the initial decrement in measured force. To determine if the whole limb force
test can result in acute muscle injury, I took advantage of fiber permeability to Evans blue dye
(EBD), as previously studied in mdx mice (Mastuda et al. 1995) (Petrof et al. 1993). There was no
obvious increase in EBD uptake when comparing strength-tested and resting mdx mice, suggesting
that the inactive state following a whole limb force test is not driven by a sufficiently high level of
acute injury to culminate in either segmental myonecrosis or prolonged sarcolemmal permeability.
This interpretation is supported by the absence of obvious acute changes in the appearance of
hematoxylin and eosin stained tissues in the comparison of force-tested to untested mdx mice
(Figure 8).

These findings prompted consideration of other mechanisms for the abrupt change in vertical
activity. Studies suggest that dystrophins role of localizing nNOs to the sarcolemma is absent in
mdx and therefore impaired vasodilatation provides a mechanistic basis for “fatigue” in muscular
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dystrophy (Kobayashi et al. 2008). This hypothesis implicates a level of muscle ischemia that would
be expected to produce significant exertional lactic acidosis. Although it is plausible to consider
acidosis as a factor impacting the behavior of mdx mice following sustained forced running, it’s an
oversimplification of the pathophysiology. These studies in mdx mice suggest that profound drop
in spontaneous activity is produced by brief periods of isometric/eccentric contraction (whole limb
force test), which represents a minimal metabolic load. Neither mdx nor control mice exhibit
measurable tachypnea during the period of reduced spontaneous activity, which would be expected
in order to compensate or recover from lactic acidemia. This argues against impaired vasodilatation
as the dominant mechanistic basis for the observed motionless behavior in our hybrid assay.

Despite the previously noted absence of any myonecrosis in mdx mice at 24 hour post-whole limb
force test (Figure 8), there is an observed dramatic spike in the serum CK levels in mdx mice
immediately following the whole limb force test (Figure 6D). While these two observations initially
appear discordant, it should be noted that serum CK was determined immediately following the
whole limb force test whereas the muscles were not analyzed for EBD fibers until 24 h postinjection. The kinetics of EBD uptake from peritoneal cavity to systemic circulation may have
allowed enough time for sarcolemmal repair. Together these results suggest that during the whole
limb force test there is acute, sublethal sarcolemmal injury that is capable of being rapidly repaired.
This is consistent with the hypothesis that a rapidly responsive sarcolemmal repair mechanism is
sufficient to prevent myonecrosis following the whole limb force test in mdx mice. The calciumactivated dysferlin pathway represents one such rapid response pathway that is capable of
explaining both the immediate rise of serum CK and the failure to observe EBD myonecrotic muscle
fibers 24 h following the whole limb force test.

In addition, to the observed decrement in spontaneous activity following the whole limb force test,
I also noticed that the mdx mice underwent periodic sporadic twitches, which resolved after a few
hours. A possible interpretation suggests the role for excitation-contraction (EC) de-coupling. Ttubules are specialized sarcolemmal invaginations that play an important role in transmitting
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electrical signals deep within a muscle fiber allowing for coordinated contraction. However, Ttubules are highly susceptible to rupture since they lie perpendicular to the axis of contraction
(Proske et al. 2001), with the potential for rapid EC decoupling. Acute loss of EC-coupling may
transiently protect a damaged fiber by inhibiting contractile activity until the focally disrupted
membrane segment is repaired to prevent further injury. Following a sublethal membrane tear,
dysferlin is recruited to injury sites within seconds and plays an important role in coordinating the
patching of the lesion through a calcium-dependent, vesicle-mediated process (Bansal et al. 2003).
Mdx mice are known to be highly susceptible to contraction-induced sarcolemmal damage and
therefore may require more time to complete dysferlin-mediated repair of ruptured T-tubules,
providing a plausible mechanistic explanation for the transient motionless behavior.

In summary, I have coupled force transduction, high precision motion tracking, and respiratory
measurement to achieve a suite of integrative physiological tests that provide novel insights into
the pathological responses to muscular exertion in the mdx mouse. By virtue of their volitional
components, the tests serve as highly informative preclinical assays that resemble primary end
points like the ones used in DMD clinical trials. I demonstrate that the significant decrement in
distance covered in the wheel by mdx mice compared with c57BL/10J non-dystrophic mice
provides a clinically relevant end point that can be used in the precise measurement of therapeutic
efficacy. I go on to demonstrate the safety of this assay by showing that serum CK levels do not
acutely rise in either control or mdx mice after voluntary, low resistance running. In addition, I have
developed a robust hybrid test that links a quantitative nonvolitional whole limb force assay to a
volitional activity measurement. Finally, in an attempt to mechanistically dissect the intriguing
observation of a drop in activity in mdx mice after the whole limb force test, I suggest a major role
for mechanisms distinct from acute muscle ischemia or myonecrosis as the dominant drivers of
performance fatigue. Regardless of the mechanism, these findings provide evidence for an
alternative sensory process that naturally restrict further muscle injury and therefore provides
translational implications in the fields of muscle biology and neuromuscular therapeutics.
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MATERIALS AND METHODS

Ethical Approval
All animal care, maintenance, and procedures were conducted in accordance with the standards
and policies of the University of Pennsylvania University Laboratory Animal Resources (ULAR) and
the National Institute of Health Guide for Care and Use of Laboratory Animals. The University of
Pennsylvania Institutional Animal Care & Use Committee (IACUC) reviewed and approved all
procedures under the protocol (#804838).

Animals
All wild type, c57BL/10J and mdx mice, c57BL/10ScSn-Dmdmdx/J were bred in house from original
strains purchased from The Jackson Laboratory (Bar Harbor, ME). A total of 76 mice, of both
genders, were used for this study. The age of the selected mice varied between 6-26 weeks with
weight in the range of 17g to 30g. Mouse housing and procedure rooms were under specific
pathogen-free conditions. Prior to all experiments, tested mice were genotyped as described
(Shrager et al. 1992). Food, water, and cracked corn bedding were provided ad libitum.

Quantification of Volitional Open Field & Running Wheel Activity
Mouse volitional activity was measured using the Fusion v5.3 SuperFlex activity monitoring cage
system (Omnitech Electronics, Columbus OH). The 16” x 16” cage had two separate ventilated
partitioned chambers, which utilize infrared beam breaks to track activity in the x, y and z plane of
motion. Each partitioned chamber had an accompanying low resistance running wheel attached
outside, which utilized magnetic sensors for precise calculations. The resolving power integrated
into this open field cage system allowed us to measure several unique parameters at a high
resolution (Nagaraju et al. 2010). (rest time, velocity in the wheel, number of wheel episodes, total
distance in the wheel/cage, vertical/horizontal activity in the cage, and other stereotypical
behavioral activity) A total of 12 c57 and 20 mdx mice, ranging from 7 weeks to 26 weeks of age
were used. Two mice were simultaneously placed into the motion tracking system, one in each
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chamber of the open field. Data was collected, exported and analyzed over the course of a 23-hour
cycle. Food, water, and cracked corn bedding were provided. In order to ensure consistency of
results, daily calibration of the running wheels was performed before and after each use.

Serum Creatine Phosphokinase (CK) assay
A total of 7 c57 and 5 mdx mice, all 6 weeks of age were anesthetized using 3-4% isoflurane, and
then maintained at 1.5% isoflurane. Serum blood was collected via venipuncture of the
submandibular vein using a 5mm animal lancet (Goldenrod Animal Lancet, Braintree Scientific, Inc,
Braintree, MA) perpendicular to the plane of the vessel. A total of 200µL was collected in a
heparinized blood collection tube (Terumo, Catalog Number: TMLH). Pressure was meticulously
applied to the venipuncture site in order to control the bleeding. The mice were monitored carefully
for 30 minutes after bleeding to observe for potential signs of adverse effects (Golde et al. 2005).
CK levels were determined by the Clinical Pathology Laboratory at the Matthew J. Ryan Veterinary
Hospital of The University of Pennsylvania.

Whole Limb Force Test & Vertical Activity
A total of 11 c57 and 21 mdx mice, ranging from 6 to 22 weeks of age were utilized to develop a
hybrid test that linked volitional activity, using the open field cage (without access to the running
wheels), to a whole limb force measurement. Mice were carefully placed in the open field cage and
their baseline vertical activity was determined for five minutes. Mice were then returned to their
original cages and allowed to rest for three minutes. An axial force transducer was used to measure
force (Vernier LabPro & Vernier Dual-Range Force Sensor ±10N, Beaverton Oregon), while data
was collected using the accompanying software (Logger Lite version 1.8.1) (De Luca et al. 2008).
To reduce chances of bias and ensure the robustness of the blinded experiment, the computer was
placed out of the scope of vision from the experimenter. The transducer was placed horizontally on
a flat surface with a stiff plastic net fastened to the metal bar. The four limbs of the mouse were
allowed to grasp the netting. Each mouse was gently pulled back by the base of its tail along the
horizontal plane of the surface until it released the net beneath. This was immediately repeated two
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more times, ensuring proper placement of the mouse’s limbs for each pull. Only the highest force
value from the series of three pulls was normalized to the mouse’s body weight (N/Kg) and reported
as the maximal force. This series of three pulls was repeated seven times with 5-minute rest periods
in between for each mouse (Table 2). Immediately after the seven series of pulls, the mouse was
placed in the open field cage for 1 hour, during which time vertical activity was recorded. All
experiments were performed by the same experimenter in a blinded fashion.

Injection of Evans Blue Dye and Immunohistochemistry
Immediately following the whole limb force test 3 mdx mice and 2 mdx mice without exposure to
the whole limb force test were injected intraperitoneally with 1% Evans blue dye (EBD, Sigma
Aldrich, Catalog Number: E2129-10G) solution injected at 1% volume relative to body mass (Hamer
et al. 2002). Twenty-four hours later, mice were euthanized by CO2 inhalation followed by cervical
dislocation (according to the 2013 AVMA Guidelines for the Euthanasia of Animals) and
gastrocnemius muscles were procured and frozen in liquid nitrogen with isopentane and then
stored in a -80oC freezer. Immunofluorescence staining was carried out on 5µm thick frozen
sections. After initial washing of the sections with phosphate buffer saline (PBS, Roche, Mannheim,
Germany) for (5 min x3), the samples were incubated for 20 minutes in a 1% solution of Triton X100 (Mannheim, Germany) pre-diluted in 0.01M PBS. The sections were then rinsed in PBS (5 min
x3) and incubated in 10% normal goat serum (Life technologies, MD, USA) for 15 min. The sections
were incubated with a rat monoclonal anti-Laminin 3 alpha antibody (4H8-2, ab11576, abcam, MA,
USA), diluted in 1:500 in PBS with bovine serum albumin (BSA) for 60 min at 37°C. Following this
procedure, the sections were washed in PBS (5min x3) and incubated in 10% normal goat serum
followed. Then the sections were incubated in goat anti-Rat lgG Alexa 488 (ab150157, abcam, MA,
USA) diluted in 1:300 for 30 min at 37°C. The sections were thereafter washed in PBS and then
mounted in Vectashield Mounting Medium (H-1500) with DAPI (Vector Laboratories, CA, USA)
(Song et al. 2012). Images were taken using Leica DM6000 at the University of Pennsylvania
Microscopy Core Facility.
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Respiratory Rate Quantification
The respiratory rate of 8 c57 and 8 mdx mice was determined by using the modular data acquisition
system (MP150 BIOPAC,) and software analysis program (the AcqKnowledge 4.2.0). Mice were
gently restrained by the scruff method and a pressure pad transducer (RX110 Biopac System, Inc)
was placed against the abdomen allowing each breath to be registered as a peak. A suitable
segment of 4 seconds with high signal to noise ratio was used to define breaths per minute (BPM)
for each animal. This method was further validated by using the Fast Fourier Transform (FFT)
option for the entire data set.

Statistics
The statistical GraphPad software (Prism 6.0f; GraphPad, San Diego, CA, USA) for Mac OSX was
used for analysis. A P-value of <0.05 was considered to be significant. P-value calculations were
made in Prism using one of the following methods: The Mann-Whitney U Test was used to examine
significant differences between the independent locomotor activities variables in each of the two
groups; The Paired t test for relating before-and-after observations on the same mice for Serum
CK.; The Pearson r correlation coefficient test for measuring the relationship between two variables
for the Serum CK and distance correlation; The Two-way ANOVA for the whole limb force test. All
described procedures and experiments were conducted in a randomized and blinded fashion.
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CHAPTER 2: SYSTEMIC ADMINISTRATION OF AAV-μUTROPHIN IN NEONATAL MDX MICE

INTRODUCTION

Currently there is no approved treatment for DMD, while most approaches are focused on
managing symptoms associated with the disease. The majority of preclinical animal studies for
DMD are done in the dystrophic mdx mouse model. Despite its mild phenotype, several histological
signs of muscular dystrophy are found in the mdx mouse model. These include a regenerative
process indicated by the presence of centrally nucleated muscle fibers, expression of protein
degradation markers, ongoing myonecrosis and mononuclear cell infiltration. AAV-mediated gene
transfer has emerged as the technology of choice for the treatment of many neuromuscular
disorders because of its ability to transduce striated muscle in a sable fashion in several animal
models, including mice. Indeed, AAV encoding truncated versions of dystrophin have been shown
to provide therapeutic benefit in mdx mice (Wang et al. 2000) (Gregorevic et al. 2006). However,
evidence of potential immune response against non-self dystrophin epitopes have been reported
(Mendell et al. 2010) (Kornegay et al. 2010)

As an alternative, we take advantage of dystrophin’s paralog protein, utrophin, which shares many
of dystrophin’s important binding domains located near the N- and C- terminus. The availability of
a paralog protein that can pitch in for the deletional nature of the disease is unique to a minority of
inherited diseases, with DMD being one them. Indeed, transgenic studies have shown that utrophin
can fully compensate for dystrophin (Tinsley et al. 1998).The earliest attempts of viral mediated
gene transfer involved the use of internally deleted vectors derived from human adenoviruses to
achieve gene transfer of full-length and shortened dystrophin. However, this approach was shortly
abandoned because of the immunogenicity and limited muscle cell transduction of the adenovirus
envelope (Clemens et al. 1996. Wakefield et al. 2000). Meanwhile, a truncated utrophin made to fit
in an AAV vector, provided benefits that rendered a milder Becker muscular dystrophy phenotype,
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since it failed to completely prevent all histological signs of muscular dystrophy in adult mdx mice
(Odom et al. 2008).

It has been suggested that age-associated differences in AAV transduction may have significant
clinical implications, since certain tissues may have developmental windows that facilitate
transduction (Bostik B. et al. 2007). Systemic delivery of AAV-μUtrophin in a neonatal setting may
increase the vector’s biodistribution since physiological diffusion barriers remain more permissible.
In addition, ongoing muscle degradation has not initiated in the neonatal setting, allowing the
therapeutic transgene to prevent, instead of halt, progression of muscular dystrophy. Here we
report on the results obtained in a blinded pre-clinical mouse study comparing vectors based on
AAV9 and the in-silico-derived ancestral capsid Anc80 (Zinn et al. 2015) to systemically deliver
codon-optimized, synthetic transgene encoding a truncated recombinant utrophin (μUtrophin) that
is driven by a constitutive CMV promoter. Transgenes encoding proteins matching the canine and
human sequences were used, since antigen-specific tolerance is easily induced by intraperitoneal
injection of AAV in neonatal mice (Shi et al. 2013). The use of canine sequences allows the
validation for future dog studies, while bypassing the use of murine sequences. Meanwhile, a
human sequence provides important pre-clinical data that can strengthen an Investigational New
Drug (IND) application for human clinical trials.
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RESULTS
In these randomized, blinded studies we were interested in investigating the degree of
myoprotection AAV-μUtrophin could provide throughout muscle development up until skeletal
maturity. Systemic delivery via an intraperitoneal injection of 2.5 x 1012 vector genomes (vg) in
neonatal mdx mice resulted in equivalent global transduction of striated muscle using both AAV9
and Anc80 (Figure 10A–E). This saturating level of expression was associated with sustained
normalization of the dystrophin-associated glycoprotein complex (DAPC), evidenced by the
positive staining of γ-sarcoglycan at the sarcolemma of representative limb muscles (Figure 10A).
Western blot analysis further confirmed that over-expression of μUtrophin in the Heart,
Gastrocnemius, and Tibialis Anterior was sufficient to stabilize the DAPC (Figure 10B). Sustained
expression of μUtrophin in skeletal and cardiac muscles was observed throughout a 16-week
period post vector delivery (the end point of study) (Figure 10C). At this dose, recombinant
μUtrophin was expressed at a level sufficient to qualitatively suppress endogenous utrophin
expression (Figure 10A), embryonic myosin heavy chain (eMHC) expression (Figure 10A),
mononuclear cell infiltration (Figure 11A), and myofiber centronucleation (Figures 11B). Serum
creatine kinase (CK) in treated mdx mice was statistically indistinguishable from that of wild-type
mice (Figure 11C).

To test whether AAV-μUtrophin confers functional improvement in mdx mice, we utilized the
established hybrid assay described in Chapter 1, that links a force grip test with the measurement
of the animals’ vertical activity post-force grip (Song et al. 2017). This hybrid assay demonstrated
an objective, dramatic and statistically significant difference between untreated and AAV-μUtrophin
treated mdx mice and was indistinguishable from that of wild-type mice (Figure 12A). Treated mdx
mice not only showed increased voluntary wheel (eight weeks) and downhill treadmill running (16
weeks) distances relative to untreated mice (Figure 12B), but their ex-vivo isolated extensor
digitorum longus muscles also displayed enhanced resistance to eccentric contraction-induced
injury (Figure 12C) as well as enhanced muscle performance in-vivo by force grip (Figure 12D).
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Figure 10. Robust and persistent expression of μUtrophin restores the DAPC
and prevents myofiber degeneration. A, Immunofluorescence staining of
representative limb muscle (tibialis anterior) for epitopes shared by native and
recombinant utrophin (Utro_N), for epitopes unique to native Utrophin (Utro_C), γsarcoglycan, eMHC and laminin. Scale bar, 25 μm. B, Western blot analysis
detecting expression of recombinant μUtrophin and γ-sarcoglycan. Gastrocnemius
(GM) and Tibialis Anterior (TA). C, Quantification of μUtrophin expression via
western blot, at eight (n = 2 mice) and 16 weeks (n = 2 mice) of age, in
gastrocnemius
(GM),
quad
(quadriceps)
and
heart
muscle.
D,
Immunofluorescence staining against utrophin N-terminus (Utro_N) and laminin in
mdx mice injected with either Anc80-μUtrophin or PBS. Muscles collected include
Heart, diaphragm, gastrocnemius (GM), tibialis anterior (TA), and quadriceps. E,
Western blot analysis of μUtrophin biodistribution in the Heart, Quadriceps (Quad),
Tibialis Anterior (TA), Gastrocnemius (GM), and Triceps. In addition, a head to
head comparison of μUtrophin expression in the TA and GM after systemic deliver
using an AAV9 or Anc80 vector. Vinculin serving as a loading control.
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Figure 11. Systemic delivery of AAV9-μUtrophin provides histological
protection, while normalizing central nuclei and serum Creatine Kinase (CK)
levels. A, H&E of representative limb muscles. Scale bar, 100 μm. B, Percentage
of centrally nucleated myofibers. For each group, n = 4 mice (distinct color), 3
muscles per mouse (distinct shape), >3 non-overlapping quantified fields/muscle.
Wild type, 0.15 ± 0.48, mdx + AAV-μUtrophin 0.86 ± 1.83, mdx + PBS 54 ± 13.
Random-effect parameters (box) were calculated as defined in the Methods. ICC,
intracluster correlation; σ2u, variance between clusters; σ2e, variance within
clusters; neff, effective sample size. C, Quantification of serum CK levels in wild
type (n = 7) 223 ± 86, mdx + AAV-μUtrophin (n = 5) 635 ± 413 and mdx + PBS
mice (n = 12) 4,744 ± 2,431.
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Figure 12. AAV9-μUtrophin treatment provides in-vivo/ex-vivo functional
improvement in mdx mice. A, Quantification of vertical activity 1 h post-grip
strength in wild type (n = 6) 1,052 ± 282, mdx + AAV-μUtrophin (n = 8) 1,279 ± 429
and mdx + PBS mice (n = 11) 522 ± 486. B, Quantification of total distance covered
on a running wheel over a 24-hour time period by mdx + AAV-μUtrophin (n = 3)
3,614 ± 300 and mdx + PBS (n = 2) 1,849 ± 259. Distance was covered via downhill
treadmill until cessation. The dashed line represents distance covered during
acclimatization prior to a ramped speed increase. Wild type (n = 4) 183 ± 0, mdx +
AAV-μUtrophin (n = 4) 174 ± 18 and mdx + PBS (n = 5) 122 ± 24 C, Absolute force
after seven cycles of eccentric contractions (ECCs) of extensor digitorum longus
(EDL) muscle in mdx + AAV-μUtrophin mice (n = 10) and mdx + PBS mice (n = 9).
Boxed values represent the fold difference of absolute force for mdx + AAVμUtrophin (ECC1 210 ± 74, ECC2 128 ± 77, ECC3 116 ± 57, ECC4 102 ± 49,
ECC5 89 ± 45, ECC6 78 ± 38) and mdx + PBS (ECC1 98 ± 49, ECC2 28 ± 17,
ECC3 27 ± 15, ECC4 20 ± 15, ECC5 15 ± 13, ECC6 14 ± 11). D, Seven serial
whole limb force measurements of wild type (n = 6), mdx + AAV-μUtrophin (n = 8)
and mdx + PBS (n = 11).
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DISCUSSION

As a strategy to overcome the potential risk of an immune response to dystrophin, we synthesized
a transgene based on the sequence of Utrophin, a protein with significant structural similarity and
normally expressed in muscles of DMD patients. Recombinant μUtrophin, was carefully truncated
and spliced to fit in an AAV vector, with an emphasis in maintaining structural strength, while
minimizing potential neo-epitopes. The goal of this study was to characterize the degree of
functional efficacy after systemic delivery of AVV-μUtrophin in a neonatal mdx mouse.

We begin at the sarcolemma where dystrophin provides a structural link between the extracellular
matrix and the cytoskeleton, while nucleating the assembly of the DAPC. In the absence of
dystrophin, the DAPC fails to assemble at the sarcolemma and myofibers become more susceptible
to contraction-induced injury. Mdx mice upregulate endogenous utrophin to sub-therapeutic levels.
(Deconinck AE et al. 1997). Therefore, in order to differentiate between native and recombinant
utrophin we rely on a double stain using antibodies specific for the N-terminus (native/recombinant)
and C-terminus (native). Tissue sections from a representative limb muscle, 8 weeks post injection
shows appropriate localization of μUtrophin to the sarcolemma, while functionally recruiting
components of the DAPC, like γ-sarcoglycan. In addition, there is a drop in expression of embryonic
myosin heavy chain (eMHC), a myosin class that is mostly expressed in regenerating fibers.
Furthermore, utrophin double stain micrographs revealed a drop in expression of endogenous
utrophin (Figure 10A), a staining pattern that is associated with myoprotection.

Western blot (WB) analysis at 8 weeks of age on representative muscles distributed throughout the
body (gastrocnemius, tibialis anterior, and the heart) further confirmed that overexpression of
μUtrophin coincided with detection of γ-sarcoglycan, once again indicating μUtrophin’s ability to
functionally stabilize the DAPC (Figure 10B). Consistent with other findings, no expression of
μUtrophin was detected in the liver since transduction of neonatal animals leads to a loss of
transduction expression over time due to the diluting effects of continuously replicating hepatocytes
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(Cunningham SC et al. 2008). This is different than in adult animals where hepatocyte turnover is
minimal and occurs relatively slower (Duncan AW et al. 2009). Persistent expression of μUtrophin
in skeletal and cardiac muscles was observed throughout a 16-week period post vector delivery
(end of study) (Figure 10C).

Pre-existing neutralizing antibodies to wild-AAV serotypes due to environmental exposure is known
to block gene transfer. Indeed, over 50% of individuals in some populations have pre-existing
immunity to AAV and are therefore excluded from participating in many AAV clinical trials (Louis
Jeune et al. 2013). With this in mind, we decided to explore the use of Anc80 (Zinn et al. 2015), an
ancestrally derived AAV vector not found in nature and therefore making it unlikely that DMD
participants who might be recruited would have pre-existing immunity. Broad biodistribution in
multiple limb, respiratory and breathing muscles was seen after systemic delivery of Anc80μUtrophin in neonatal mdx mice (Figure 10D). WB analysis shows no difference in level of
μUtrophin expression in a head-to-head comparison between AAV9 vs Anc80 in the gastrocnemius
and tibialis anterior muscles (Figure 10E).

In AAV-μUtrophin treated mdx mice there is a vast reduction in mononuclear cell infiltrates, fibrosis,
and overall inflammation in representative forelimb (triceps) and rear limb (quadriceps) muscle
sections stained with H&E (Figure 11A). The ongoing degenerative and regenerative process in
mdx mice is manifested by a large percentage of centrally nucleated myofibers. Skeletal Muscle is
characterized by having peripheral nuclei. In WT, less than 1% of myocytes are centrally nucleated.
Meanwhile, Mdx muscle will have around 60% of its myocytes centrally nucleated. For the first time,
we report a complete normalization of central nuclei, the most sensitive marker of myoprotection in
AAV-μUtrophin treated mice (Figure 11B). Another first in its kind result was the complete
normalization in treated mdx mice of serum CK levels (Figure 11C), an important biomarker that
reflects sarcolemmal permeability. Other approaches which involve administration of alternative
transgenes via tail vein injection after the onset of myopathology managed to reduce levels of
serum CK, however nowhere near wild type levels (Gregorevic et al. 2004) (Odom et al. 2008;)
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(Kennedy et al. 2018). Meanwhile, in an ex-vivo study, isolated extensor digitorum longus (EDL)
muscles from AAV-μUtrophin treated mdx mice, regardless of gender, displayed a highly significant
resistance to force drop following a series of six eccentric contractions (Figure 12C).

A further encouraging finding from this study was the observed functional improvement in several
in-vivo assays. Treated mdx mice showed an increase in voluntary wheel and downhill treadmill
running distances relative to untreated mice (Figure 12B). In Chapter 1 I focused on establishing a
hybrid assay linking vertical activity with a whole limb force grip, which provided one of the most
sensitive and clinically relevant parameters distinguishing mdx from wild-type mice. In this hybrid
assay a profound drop in vertical activity is generated after a whole limb force test. Neither fulllength utrophin or μUtrophin contain an nNOS-binding motif normally found in dystrophin’s 16-17
spectrin-like repeat. This motif is associated with localizing nNOS to the membrane and therefore
contributes to ways in which vessels can vasodilate and provide oxygen and nutrients in muscle.
However, neither mdx nor control mice exhibit an increased breathing rate during the hybrid test
(Figure 9), which would be expected if the animals were becoming acidotic due to inappropriate
vasodilation as suggested by other groups (Kobayashi et al. 2008). Surprisingly, AAV-μUtrophin
treated mdx mice exhibit an improvement in the whole limb force test after a series of seven pulls
(Figure 12D), but more importantly demonstrate a complete normalization of post-vertical activity
(Figure 12A). These results suggest that proper nNOS localization is not solely responsible for the
observed inactivity. Additional studies may be necessary to further understand and mechanistically
dissect other compensatory pathways that may be involved.

Taken together, these findings suggest that early overexpression of μUtrophin is capable of full
phenotypic amelioration in the absence of full-length dystrophin, despite the comparatively short
length and the lack of an R16–17 nNOS-binding motif. Delivery of AAV-μUtrophin in neonatal mdx
mice is able to achieve widespread and persistent transduction of striated muscles. Overexpression
of μUtrophin resulted in complete histological protection, with prevention of all signs of muscular
dystrophy, normalization of central nuclei and normalization of serum CK to wild type levels. We
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are the first to report all of these findings. In addition, μUtrophin provided functional improvement
in an array of ex- and in-vivo assays. Although these results are encouraging, assessing this
approach in larger more physiologically relevant animal models will be necessary in order to further
understand the potential immune responses of the host against both the viral capsid and the
therapeutic transgene.
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CHAPTER 3: SYSTEMIC ADMINISTRATION OF AAV-μUTROPHIN IN NEONATAL AND
JUVENILE GOLDEN RETERIEVER MUSCULAR DYSTROPHY (GRMD) CANINE MODEL

INTRODUCTION

Promising results in the smaller mdx mouse model summarized in Chapter 2 encouraged us to
translate our approach in the larger Golden Retriever Muscular Dystrophy (GRMD) canine model.
Unlike the mdx mouse, which shows relatively mild clinical signs, the GRMD develops a severe
progressive phenotype strikingly similar to DMD in humans, has a well-defined natural history, and
a physiology that more closely resembles humans. In addition, mice have not been great models
for predicting cellular and/or humoral immunes responses to the viral capsid and/or therapeutic
transgene (Duan et al. 2011) (Arruda et al. 2004). Accordingly, studies in the GRMD model are
better suited to predict pathogenesis and treatment outcomes in DMD. In this chapter I will discuss
the histological and immunological consequences of systemic AAV-μUtrophin gene transfer in
neonatal and juvenile GRMD.

The GRMD model arose from a single point mutation in intron 6 of the DMD gene, however due to
alternative splicing, the mutation can actually be skipped over by the ribosome, resulting in
detectable levels of “near full-length,” which is enough to “tolerize” the immune system. As a result,
potential autoreactive dystrophin-specific T-cells are appropriately negatively selected at the
thymus during development, thus establishing central tolerance. Because of the latter process, the
GRMD model can fail to expose some of the immunological consequences from long-term bodywide expression of dystrophin-based transgenes. This therefore complicates the interpretation of
several preclinical studies (Schatzberg et al. 1998) (Yue et. al, 2015) (Le-Guiner et al. 2017).

Analogous with the rationale in the mouse studies described in Chapter 2, a systemic administration
of AAV-μUtrophin in the neonatal dog was done in order to take advantage of the relative immaturity
of the neonatal immune system (Bostik et al. 2011). Two of ten GRMD puppies (4–7 days of age)
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were randomized to an intravenous administration of AAV-μUtrophin at dose of 1 x 1013 vg/kg and
3.2 x 1013 vg/kg at the time of injection, without immunosuppression. Meanwhile, to explore the
feasibility of the approach in young boys with DMD, two juvenile GRMD dogs at 7.5 weeks of age
(Hann and Beetle) were injected intravenously with AAV-μUtrophin at a dose of 1.25x1014 vg/kg
and 5x1013 vg/kg respectively with a transient dose of prednisone (1 mg/kg daily) (Figure 14). One
of the major limitations of these proof-of-concept studies stems from the 1,000-fold difference
between the adult weight of mdx mice and GRMD dogs, 25 g and 25 kg, respectively. At this vector
dose, the dogs would inevitably ‘outgrow’ the vector. As a result, I focused on early histological
evidence for myocyte protection and potential immune responses to vector and/or therapeutic
transgene.
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RESULTS

Neonatal GRMD dogs were randomized to receive a systemic administration of AAV-μUtrophin at
doses of 1 x 1013 vg/kg and 3.2 x 1013 vg/kg, without immunosuppression. Treated dogs achieved
a fourfold increase in weight, similar to that of their littermate carrier females (F-carrier3, F-carrier4,
F-carrier6) (Figure 13A). Six weeks post injection immunofluorescence micrographs show robust
μUtrophin expression and stabilization of wild-type levels of γ-sarcoglycan expression in the
sarcolemma (Figure 13C). H&E staining of vastus lateralis muscle biopsies suggests that this
sustained μUtrophin expression was associated with visibly reduced levels of myonecrosis,
mononuclear infiltration (Figure 13B). At five- and eight-weeks post vector administration, canine
interferon-γ ELISpot assays revealed no cell-mediated immunity against either the AAV capsid or
the μUtrophin transgene product in these non-immunosuppressed treated GRMD dogs (Figure
13D).

In the juvenile GRMD studies, dogs (Hann and Beetle) were injected intravenously with AAVμUtrophin at a dose of 1.25 x 1014 vg/kg and 5 x 1013 vg/kg respectively at 7.5 weeks of age. Both
animals were administered a transient use of an anti-inflammatory dose of prednisone, 1 mg/kg
daily (Liu et.al, 2004). Blood draws were done before infusion and then weekly, muscle biopsy of
the Vastus Lateralis and Cranial Sartorius 4 weeks post injection, and necropsy at 7 weeks post
injection (Figure 14). Immunostaining of muscle biopsies showed homogeneous sarcolemmal
expression of μUtrophin, suppression of native utrophin, as well as rescue of the several
components of the DAPC (Figure 15A). This was further confirmed by western blot of muscle
biopsies of the Vastus Lateralis and Cranial Sartorius collected 4 weeks post injection (Figure 15B).
Further western blot analysis at necropsy showed persistent widespread expression of μUtrophin
in locomotion (Biceps Branchii, Biceps Femoris), cardiac, jaw closing (temporalis), and breathing
(diaphragm) muscles (Figure 15C). Histopathological characterization of limb muscle from treated
GRMD dogs demonstrates near-complete suppression of ongoing muscle injury, as evidenced in
untreated age-matched controls by a high rate of myonecrotic fibers, excessive calcium
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accumulation, clustered regenerating muscle fibers, abundant inflammatory cell infiltration and fat
infiltration (Figure 16A-D). AAV9-μUtrophin treated dogs also showed nearly complete prevention
of muscle degeneration and regeneration in masticatory muscles (Figure 16A, B). In addition,
Vastus Lateralis muscle biopsies obtained at 4 weeks post injection and at necropsy indicate
normalization of myofiber minimal Feret diameter (Figure 16E, F). Surprisingly, an 80% drop in
serum CK levels was measured one-week post-infusion at both doses (Figure 17). Blood tests
done before and after vector administration remain unchanged and show no signs of toxicity (Figure
18A). Consistent with the previous GRMD neonatal dog studies, interferon-γ ELISpot assays
revealed no signal above background against μUtrophin (Figure 18B).
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Figure 13. Neonatal Golden Retriever Muscular Dystrophy (GRMD) dogs
randomized to AAV-μUtrophin results in normal growth and provides
histological improvement without any signs of toxicity. A, Individual weights
of dogs randomized to the highest doses (3.2 x 1013 vg/kg) of AAV-μUtrophin
without immunosuppression (F[b] AAV-cU, F[c] AAV-cU), as well as relevant
controls including littermates randomized to PBS and other littermate carrier
females (F-carrier3, F-carrier4, F-carrier6) and non-littermate GRMD males (MGRMD7, M-GRMD8) and females (F-GRMD9, F-GRMD10). Also included for
comparison are relevant weights of previously reported GRMD females receiving
human μDystrophin (F[e] AAV-hD, F[f] AAV-hD) showing rapid weight loss
immediately prior to euthanasia and necropsy showing signs of systemic myositis
(Kornegay et al. 2010). Graphical depiction of Animal ID#, creatine kinase (CK)
levels at birth, GRMD status by PCR, and weight at two time points for littermates
of AAV-μUtrophin injected dogs. B, H&E staining of vastus lateralis muscle
biopsies. Scale bar, 100 μm. C, Immunofluorescence staining detecting the
utrophin N terminus (Utro N, red) and β-sarcoglycan (green) of vastus lateralis
muscle from wild type (WT), treated (AAV-μUtrophin) or untreated (PBS). D, γInterferon production was quantified by counting the spot forming units (SFUs) per
million peripheral blood mononuclear cells (PBMCs). A response above the dotted
line is considered positive and above the background signal. Peptide libraries used
represent the full sequence of AAV9 capsid (A–C), μUtrophin (E–J), Adenovirus5
(1–4) and LacZ (1–4).
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Figure 14. Experimental timeline for juvenile GRMD studies. Intravenous
delivery of AAV9-μUtrophin in two juvenile GRMD dogs at seven and half weeks
of age (53 days). Low dose of 5 x1013 vg/kg and a high dose 1.25 x1013 vg/kg.
Blood was collected at several time points for creatine kinase (CK) measurements.
Muscle biopsy of Vastus Lateralis and Cranial Sartorius at 4 weeks post injection
(83 days). Necropsy 7 weeks post injection (102 days).

Figure 15. Widespread expression of μUtrophin functionally rescues
components of the DAPC in treated juvenile GRMD dogs. A,
Immunofluorescence staining of representative limb muscles against native and
recombinant utrophin (Utro_N), native utrophin (Utro_C) and β-sarcoglycan
(green), γ-sarcoglycan (green) and β-dystroglycan (red). B, Western blot analysis
of μUtrophin (~135 kDa) in muscle biopsies of vastus lateralis and cranial sartorius
and the expression β-dystroglycan with Vinculin serving as a loading control C,
and of several tissue collected at necropsy; Bicep Branchii (BB), Bicep Femoris
(BF), Heart (H), Temporalis (T), Liver (L), and Diaphragm (D).
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Figure 16. Systemic delivery of AAV9-μUtrophin in juvenile GRMD dogs
prevents myonecrosis and provides near-complete histological suppression
of ongoing muscle injury. A, Representative H&E of vastus lateralis and
temporalis muscle. D, Alizarin Red S and Wheat Germ Agglutinin (WGA) staining
of tibialis anterior muscle (Scale bar, 100 μm), with corresponding quantification of
calcified fibers per area. For wild type (n = 5) 0 ± 0, GRMD + AAV-μUtrophin (n=5)
1.5 x 10−6 ± 1.6 x 10−6 and GRMD + PBS (n = 5) 3 x 10−5 ± 1.4 x 10−5. C,
Immunofluorescence staining of tibialis anterior muscle for embryonic Myosin
Heavy Chain (eMHC) (Scale bar 100 μm), with corresponding quantification of
eMHC positive fibers. For wild type (n = 5, ≥1 image field per muscle) 0 ± 0, GRMD
+ AAV-μUtrophin (n = 6, 2 image fields per muscle) 4 ± 1.9 and GRMD + PBS (n
= 6, 2 image fields per muscle) 30.6 ± 10.5. E, Distribution of minimum Feret
diameter of myofibers in vastus lateralis muscle biopsies pooled from age-matched
wild type (n = 920) 19 ± 4, GRMD littermates randomized to AAV-μUtrophin (n =
758) 17.6 ± 4.9, and PBS (n = 1,014) 14.5 ± 7.24. F, Distribution of minimum Feret
diameter of myofibers in vastus lateralis muscle biopsies obtained at necropsy,
wild type (n = 569) 28 ± 8.4, AAV-μUtrophin (n = 542) 28 ± 7.5 and PBS (n = 317)
32 ± 12. Coefficients of variation for all groups are reported in the box and the
cumulative distribution (%) plot of minimum Feret diameter is shown on the side.
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Figure 17. Serum CK levels, at various time points pre- and post-systemic
delivery of AAV9-μUtrophin at two doses: 1.25 x 1014 vg/kg and 5 x 1013 vg/kg.

Figure 18. μUtrophin expression in juvenile GRMD dogs shows no signs of
toxicity and is protected by central tolerance. A, Measurement of alkaline
phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase
(AST), hemoglobin, and platelets before and after AAV-μUtrophin injection in two
juvenile GRMD dogs (Hann/Beetle). Non-human primate (16C176 and RA2152)
data are incorporated to illustrate the absence of disseminated intravascular
coagulation (Hinderer et al. 2018; Hordeaux et al 2018). B, No evidence of a cell
mediated immune response against μUtrophin via an γ-interferon ELISPOT assay
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DISCUSSION

A neonatal systemic gene transfer approach offers the possibility of an early preventative treatment
before the onset of irreversible muscle damage. It also minimizes the risk of an immune reaction
against vector capsid antigens, as memory T cells and neutralizing antibodies recognizing an AAV
capsid develop through serial environmental exposure (Nichols et al. 2015) (Calcedo et al. 2011).
In addition, a relative immature immune system is less likely to target transgene epitopes.

In the first study, neonatal GRMD dogs were given an intravenous injection of AAV-μUtrophin at a
dose of 1x1013 vg/kg or 3.2x1013 vg/kg, without immunosuppression and achieved a fourfold
increase in weight, similar to that of their littermate carrier females (F-carrier3, F-carrier4, Fcarrier6) (Figure 13A). These results are consistent with other groups using a canine dystrophin
derived transgene (Le-Guiner et al. 2017), to achieve rescue, but differ in weight decrement in
GRMD (F[e] AAV-hD & F[f] AAV-hD) associated with immune myositis following systemic
administration of a human dystrophin derived transgene (Kornegay et al. 2010). Muscle biopsies
at 6 weeks post infusion showed how robust μUtrophin expression at the sarcolemma was
accompanied by functional restoration of the DAPC (β-sarcoglycan) (Figure 13C). In addition, H&E
staining suggests that this sustained μUtrophin expression was associated with visibly reduced
levels of myonecrosis and mononuclear infiltration (Figure 13B). Dystrophic muscles are constantly
undergoing a degenerative/regenerative process resulting in a broader range of muscle fiber
diameter. This morphometric variability can be quantified and used as a surrogate for the degree
of injury (Judith Dubach-Powel et al. 2014).

Peripheral blood mononuclear cells (PBMCs) were collected at 5- and 8-weeks post injection. At
both time points, canine interferon-γ ELISpot assays revealed no cell-mediated immunity against
either the AAV capsid or the μUtrophin transgene product, consistent with central immunological
tolerance (Figure 13D). Meanwhile, an important positive control for this experiment was a dog
injected with Adenovirus-CMV-lacZ, which as expected, showed a positive response to lacZ
peptide pools.
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The majority of DMD patients are diagnosed after the age of two years, by which time massive
muscle fiber degeneration, necrosis with mononuclear cell invasion and increased fiber size
variability have already occurred (Yiu et al. 2015). To explore the feasibility of an intravenous gene
transfer approach in young boys with DMD, two juvenile GRMD dogs (Hann and Beetle) were
injected intravenously with AAV9-μUtrophin at either a high dose of 1.25 x 1014 vg/kg or low dose
of 5 x 1013 vg/kg at 7.5 weeks of age. Both animals were administered a transient use of an antiinflammatory dose of prednisone, 1 mg/kg daily (Liu et al. 2004). Blood was collected at several
time points for creatine kinase (CK) measurements. Muscle biopsy of Vastus Lateralis and Cranial
Sartorius at 4 weeks post injection and a necropsy 7 weeks post injection (Figure 14).

In order to determine the benefits in treated animals we used a variety of histological assays. Once
again, a double stain using antibodies specific for the N-terminus (native/recombinant) and Cterminus (native) was used in order to differentiate between native and recombinant utrophin.
Immunostaining of muscle biopsies taken four weeks post injection, showed homogeneous
sarcolemmal expression of μUtrophin, suppression of endogenous utrophin and functional rescue
of multiple components of the DAPC, β/γ Sarcoglycan and β-Dystroglycan. (Figure 15A). This was
further confirmed by western blot in muscle biopsies collected 4 weeks post injection (Figure 15B).
In addition, there was a persistent widespread expression in skeletal, respiratory and cardiac
muscles collected at necropsy 7 weeks post injection (Figure 15C).

Protection of the powerful jaw closing muscles, like the temporalis, is of significant pathobiological
interest due to the unique phenotype of trismus and difficulty chewing associated with the GRMD
model. These masticatory muscles express the powerful MYH16 myosin isoform (Stedman et al.
2004) (Toniolo et al. 2008), thus making them highly susceptible to injury in the dystrophin null
setting. It’s encouraging to see that H&E staining of the temporalis showed a vast reduction in
mononuclear cell infiltrates, fibrosis, and overall inflammation (Figure 16A). Furthermore,
temporalis muscle obtained at necropsy show a homogenous distribution of the uniquely expressed
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MYH16 in treated dogs, compared to the sparse levels of expression seen in non-treated dogs
(Figure 16B). A near-complete suppression of ongoing muscle injury was indicated by the
quantified drop in excessive calcium accumulation observed by an Alizaren Red and eMHC stain
(Figure 16C, D). In addition, vastus lateralis muscle biopsies obtained at 4 weeks post injection and
at necropsy indicate normalization of myofiber minimal Feret diameter (Figure 16E, F).

Surprisingly, an abrupt 80% drop in serum CK levels was measured one-week post-infusion in both
treated dogs (Figure 17). The sluggish rise in serum CK levels post one-week infusion is most likely
due to the rapid growth of the animal, thus diluting the therapeutic effects of μUtrophin and therefore
reiterating the importance of focusing on early histological evidence for myocyte protection.

Consistent with the previous neonatal GRMD studies, administration of AAV-μUtrophin in juvenile
animals did not result in signs of toxicity at any of the tested doses, in contrast to previous studies
using xenogenic human dystrophin in GRMD dogs (Kornegay et al. 2010) and the presence of
disseminated intravascular coagulation (DIC) seen in non-human primates. (Hinderer et al. 2018)
(Hordeaux et al. 2018). Blood tests included electrolytes, kidney and liver function parameters and
complete hematology counts.; alkaline phosphatase (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), hemoglobin, platelets and γ-interferon remained unchanged
weeks after vector delivery (Figure 18A). To further broaden our immunological study, I generated
a second positive control by synthesizing a mini peptide pool composed of sequences derived from
capsid proteins frequently used to vaccinate and boost dogs against canine distemper and parvo
virus. An interferon-γ ELISpot assays revealed no signal above background against μUtrophin
(Figure 18B). Taken together, these results show that the delivery of AAV-μUtrophin in both
neonatal and juvenile GRMD dogs show no signs of adverse effects or toxicity. Widespread and
persistent expression of μUtrophin resulted in near-complete histological protection and an abrupt
drop in serum CK. No cell mediated immune response was detected against the capsid or
transgene at any of the evaluated systemic doses or at any age.
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CHAPTER 4: ASSESSMENT OF IMMUNOGENICITY TO UTROPHIN AND DYSTROPHIN
EPITOPES IN THE GERMAN SHORTHAIRED POINTER MUSCULAR DYSTROPHY
(GSHPMD) CANINE MODEL

INTRODUCTION

An ongoing concern in gene therapy is the potential for a harmful immune recognition of
recombinant dystrophin in DMD subjects (Mendell et al. 2010), as most cases are caused by multiexon frame shifting deletions within the DMD gene. In contrast, the genetic basis of the GRMD
dog is a single base intron splice mutation that leaves the entire dystrophin coding sequence intact
(Sharp et al. 1992). Muscle from GRMD dogs have been found to express detectable amounts of
near-full length dystrophin by means of alternative exon splicing (Schatzberg et al.1998), making
the GRMD a less reliable model to assess immune responses for a dystrophin-based approach.

Thus far, preclinical studies in the mdx murine and GRMD canine model suggests that an AAVμUtrophin gene transfer approach holds just as much, or perhaps more promise for the treatment
of DMD, as the three other microdystrophin-based approaches currently in human clinical trials
(Sarepta-NCT02376816, Solid–NCT03368742, Pfizer- NCT04281485). However, in order to fully
characterize μUtrophin’s safety profile with the prospect of minimizing the risk to the patients we
decided to stringently evaluate delivery of μUtrophin in a more informative model. For a more
rigorous preclinical assessment of vector and/or transgene immunotoxicity, we took advantage of
the recently characterized German Shorthaired Pointer Muscular Dystrophy (GSHPMD) deletionalnull canine model (Schatzberg et al. 1999) (VanBelzen et al. 2017). The GSHPMD lacks the entire
DMD gene and therefore is void of any possible level of immunological tolerance or sensitivity to
wild-type dystrophin epitopes. Thus, this model provides a superior platform for the prediction of
immune responses to gene therapies for DMD. The GSHPMD model allows us to test the following
working hypothesis; expression of μUtrophin will be protected by central tolerance, while
μDystrophin will drive an unwanted, harmful auto-immune response.
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RESULTS

Adult GSHPMD dogs (Ned and Grinch) each received equivalent doses (2 x 1012 vg/kg) of both
AAV9-μDystrophin (Right) and AAV9-μUtrophin (Left) via a contralateral intramuscular injection
into the tibialis muscle (Figure 19). H&E analysis showed severe inflammation and mononuclear
cell infiltration on the μDystrophin-injected side compared to their virtual absence on the μUtrophininjected side (Figure 20A). Similarly, immunofluorescence co-staining of muscle biopsies against
CD3+ and CD8+ were only found on AAV-μDystrophin injected side (Figure 20B). Immunostaining
of muscle biopsies collected four weeks post-injection revealed persistent expression of μUtrophin,
but only sparse amounts of μDystrophin (Figure 21A). In order to ensure that we were detecting
recombinant Utrophin and not endogenous utrophin, double staining using Utro_N (recombinant)
and Utro_C (native) were used (Figure 21B). Peripheral blood was collected pre-, 2, 4, 6, 8 weeks
post-injection in order to isolate peripheral blood mononuclear cell’s (PBMC’s). Finally, interferonγ detection via ELISPOT revealed the presence of a strong cell mediated immune response against
μDystrophin, as early as two weeks post-injection, but not to μUtrophin (Figure 22).

Figure 19. Experimental timeline for German Shorthaired Pointer studies. A,
Each dog received intra-muscular injections of both AAV-μDystrophin (left) and
AAV-μUtrophin (right) at equivalent doses (2 x 1012 vg/kg) into their tibialis anterior
compartment. Blood was collected in order to isolate Peripheral blood
mononuclear cells (PBMCs) pre- and 2,4,6,8-weeks post-injection. Muscle biopsy
of the vastus lateralis were scheduled at 4 weeks post injection.
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Figure 20. In the GSHP canine model, μDystrophin, but not μUtrophin, elicits
a local inflammation and a cell mediated immune response after an
intramuscular injection. Muscle biopsies were obtained four weeks postintramuscular injection of μDystrophin and μUtrophin. B, Immunofluorescence
staining of muscle biopsies against CD3+ and CD8+. The bottom merged panel
offers a validation of both antibodies. All experiments were repeated independently
at least two times with similar results.

Figure 21. Robust expression and localization of μUtrophin, but not
μDystrophin. Immunofluorescence staining of muscle biopsies collected four
weeks post-injection A, against utrophin (green) and dystrophin (red). B,
Immunofluorescence staining of muscle biopsies against Utro_N (recombinant)
and Utro_C (native). Scale bar, 50 μm.
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Figure 22. Focal expression of μDystrophin, but not μUtrophin, elicits a
detectable peripheral immune response in the GSHP dystrophin deletionalnull dog model. Peripheral blood mononuclear cells (PBMCs) collected pre- and
two, four, six and eight weeks post-injection were cultured with synthetic peptides
spanning the entire μDystrophin (pool A–D) and μUtrophin (pool E–J) peptide
sequences, while vaccine peptides and phorbol myristate acetate
(PMA)/ionomyocin served as positive controls. A positive result is interpreted as
≥5 spot forming units (SFU) per 1 x 105 PBMCs (dotted line).
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DISCUSSION

In many genetic diseases where a protein is mutated or altogether absent there is a failure of
establishing immunological tolerance to its wild-type form. Thus, gene therapies that deliver a
transgene modeled after a wild-type protein risk provoking an unwanted immune response (Moore
et al. 2010). Chapter 2 and 3 outlines the efficacious results of an AAV-μUtrophin approach in the
two most commonly used animal models. The mdx mouse model results from a nonsense point
mutation within exon 23 (Sicinkski et al. 1989), while the GRMD dog results from a point mutation
within the splice acceptor site of intron 6 (Sharp et al. 1992). Both mutations represent a tiny fraction
of those seen in the DMD patient population, thus can fail to expose some of the immunological
consequences from long-term body-wide expression of dystrophin-based gene therapies.

Despite this, three human clinical trials relying on systemic delivery of AAV-microdystrophin for the
treatment of DMD have made their way into the clinic. However, several things can make predicting
immune responses following these treatments extremely challenging. First, each trial is using a
unique microdystrophin construct. Second, each trial has a different inclusion criterion in regard to
the subject’s dystrophin mutation. Sarepta-NCT02376816 trial only enrolls subjects who carry
specific mutations (confirmed DMD mutation between exons 18-58), while Solid–NCT03368742
and Pfizer-NCT04281485 are open to subjects with any DMD mutation (Duan et al. 2018). Lastly,
is the concern of revertant fibers, which results from leaky dystrophin expression due to alternative
splicing and stop codon readthrough (Pigozzo et al 2013) (Hoffman et al 1990), thus establishing
varying degrees of tolerance against dystrophin during development. In addition, revertant fibers
have also been shown to prime unwanted immune responses against dystrophin peptides (K. M.
Flanigan et al, 2013) (Mendell et al. 2010). Nonetheless, non-peer reviewed data releases from
corporate sponsors from the three trials indicate a mixture of results. Transient drop in serum CK
levels, recombinant dystrophin expression in muscle biopsies, statistically insignificant
improvements in clinical performance in open label study, were offset by numerous SAEs including
rhabdomyolysis, severe acute renal failure requiring ICU admission and hemodialysis, as well as
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manufacturing concerns (https://www.parentprojectmd.org/?s=adverse). Up to this date, the
disclosure of all adverse events has not been accompanied with any data that can help researchers
further understand and avoid these effects.

In order to improve the ability to predict immune responses using a μUtrophin gene transfer
approach, we decided to use the recently described, naturally occurring GSHPMD deletional-null
canine model (VanBelzen et al. 2017). The GSHPMD should be void of immunological tolerance
to all dystrophin epitopes and therefore should provide the best opportunity to truly expose any
potential immune responses to dystrophin-based gene therapies, while elevating μUtrophin’s safety
profile.

At the time of the experiment, there were only two affected GSHPMD dogs that existed in the world,
so extra close attention was placed to many details in the design and execution of this experiment.
One of our biggest concerns was minimizing any potential for breaking tolerance against the
transgenes, as was reported in other overexpression studies (Guangping Gao et al. 2004) (Pierre
Chenuaud et al 2004).Therefore, getting the dosing right was instrumental. For guidance on vector
dose, I leaned on my colleagues who have decades of experience in gene therapy pre-clinical
canine studies for Hemophilia (Herzog, R. et al. 2002) (Arruda et al. 2004). Details such as needle
gauge, volume, time needle is left in the muscle, rate at which vector is administered, tattooing,
and distance between injections, were all taken into consideration. We administered an equivalent
focal dose (2 x 1012 vg/kg) of AAV-μDystrophin (left) and AAV-μUtrophin (right) in two nonimmunosuppressed GSHPMD dogs with the ultimate goal of tracking the subsequent immune
responses against both recombinant transgenes.

Four weeks post-injection muscle biopsies at the site of AAV- μDystrophin and at the equivalent
site in the contralateral AAV- μUtrophin injected site were collected and H&E stained. Only the
μDystrophin-injected side revealed severe inflammation, fibrosis, and mononuclear cell infiltration,
while the μUtrophin-injected side showed no signs of injury or inflammation (Figure 20A). These
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findings indicate that the observed immune response is driven solely by the μDystrophin transgene
and not the vector capsid or route of administration, since equivalent doses of the same vector
were used on both sides. In order to further characterize the cell population that had migrated to
the site of injection and was driving this local inflammatory response, muscle biopsies were stained
against markers for cytotoxic t cells (CD3+ and CD8+). Confirmed co-staining for CD3+ and CD8+
were found only on the μDystrophin-injected side and not on the μUtrophin-injected side (Figure
20B), consistent with the H&E staining. Immunostaining against both recombinant μDystrophin and
μUtrophin showed very distinct expression patterns, where μUtrophin localized properly to the
sarcolemma. Meanwhile μDystrophin was found sparsely expressed in the cytoplasm, suggesting
that these myofibers indeed were transduced but are undergoing a degradation process (Figure
21A).

Finally, an ELISPOT using peripheral blood mononuclear cells (PBMCs) collected pre-, 2, 4, 6, 8
weeks post-injection showed a multi-log cell mediated immune response against a broad range of
μDystrophin epitopes as early as two weeks post-injection, but not to μUtrophin (Figure 22). As an
additional positive control, we relied on the fact that these dogs had been intentionally vaccinated
against canine parvovirus and distemper virus, which allowed us to use the actual heat inactivated
vaccine as a source of an antigen. These results highlight the strength of central tolerance since
our transgenes were delivered via a highly immunogenic route of administration, in dystrophic
tissue with heightened immune activity, using a constitutive CMV promoter, yet we see no immune
response against μUtrophin.
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METHODS FOR CHAPTERS 2-4

μUtrophin Transgene Design and Vector Production
Based on phylogenomic analysis of sequence conservation and genotype-phenotype correlations
among BMD/DMD patients, we modeled in silico the spectrum of AAV-encodable miniaturized
utrophins that preserve the calponin homology domains, the first three and last three spectrin-like
repeats, and the combination of the WW, EF hand, and ZZ domains. To preserve amino acid
side chain interactions between interhelical loops of adjacent spectrin-like repeats, we focused on
only the subset of µUtrophin in which either the first or last three repeats were preserved intact.
To minimize immunogenicity in dogs, we considered only those µUtrophin that could be created
by the combination of a single internal deletion and a C-terminal truncation. Although the
spectrin-like repeats are homologous to a consensus sequence, the divergence is such that no
splice could be found between identical decapeptides in any of the mammalian utrophins. Thus,
we used profile Hidden Markov Models, as implemented online at
http://hmmer.janelia.org/search/hmmscan, to define and annotate spectrin-like triple helical repeat
boundaries in the full length murine, canine, and human utrophin sequences (e. g. 3456 aa,
XP_005615306). We used transgenes encoding proteins matching the canine and human
proteins in neonatal mice, in which antigen-specific tolerance is easily induced by intraperitoneal
injection of AAV (Shi etal. 2013), but only the canine versions in neonatal and older dogs in which
tolerance is anticipated to require earlier prenatal exposure to the isogenic native protein during
immune ontogeny (Davey et al. 2017). The µUtrophin transgenes were designed to contain the
actin binding domain, triple helical repeats 1-3 and 22, a disordered, proline-rich region
approximating that previously identified as “hinge” 2, and the C-terminal WW, EF hand, and ZZ
domains, thus creating recombinant proteins designed to match the canine and human utrophin
sequences with the exception of a single splice site at the deletion junction, thereby minimizing
potential immunogenicity in dystrophin deficient dogs, and ultimately humans, relative to
previously reported transgenes (Wang, B. et al. 2000) (Haprer et al. 2002) (Gregorevic et.al.
2004) (Odom et al. 2008). The coding sequence chosen for use in these studies was selected as
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the highest-expressing candidate of a pool of cDNAs that were optimized and synthesized by
competing biotech companies (GeneArt and DNA 2.0).

Animals
The Animal Care and Use Committee of the A&M University and the University of Pennsylvania
approved all animal experiment protocols in mice and dogs.

Murine Model Vector Administration
Mouse strains C57BL/10SnJ and mdx were purchased from the Jackson laboratory (Bar Harbor,
ME). This study involved 23 C57BL/10SnJ mice and 30 mdx mice, all injected at 9 ± 2 days of age.
Prior to receiving intraperitoneal injection of AAV9-μUtrophin or Phosphate Buffered Saline (PBS),
individual pups were toe-tattooed with the Aramis Micro tattoo kit (Ketchum Manufacturing Inc,
Canada) and randomly assigned to different dosage groups. Investigators were blinded during all
injections and tissue harvesting. Based on this protocol, C57BL/10SnJ and mdx pups were injected
with 50 – 250 μl of either PBS as negative control or AAV9-μUtrophin diluted in PBS via 32-gauge
insulin syringe. Prior to injection, each mouse was weighed. After vector administration, all mice
were returned to their litters and separated after weaning.

Murine Model Tissue Procurement and Storage
At approximately 8 weeks of age, mdx and C57BL/10SnJ mice underwent CO2 euthanasia in
accordance with the institutional policy. The heart, tibialis anterior, gastrocnemius, quadriceps,
triceps, abdominal, diaphragm, temporalis muscles, and liver were harvested and further
processed; others were stored but not utilized based on studies showing < 100-fold lower off-target
gene expression with AAV9 in mice 48. Designated histological tissue samples were placed in OCT
(Tissue - Tek) containing embedding molds (Richard-Allan Scientific) and rapidly frozen in liquid
nitrogen-cooled isopentane. Additional designated biological tissue samples were placed in tissue
containers and rapidly frozen in liquid nitrogen. All the specimens were stored at -80*C.
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Cryosections of 5-7 μm thickness were cut on a cryostat (Microm™ HM550, Thermo Scientific,
USA) at -25*C and mounted on glass slides (Superfrost Plus, Fisher Scientific, USA).

Basic Histology - Hematoxylin and Eosin staining (H&E) and Alizarin red staining (ARS)
7 μm thick cross sections were air dried for 15 min at room temperature. Then the slides were
stained with Harris’ hematoxylin dye for 2.5 minutes, rinsed in distilled water, dipped in 0.1% acetic
acid for 15 seconds, followed by a repeat rinse in tap water for 4 mins and counterstaining with 1%
eosin for 1 min. As a final step, the slides were dehydrated in ethanol three times, 2 mins each.
Representative, non-overlapping high-powered fields (HPF) were photographed for scoring.
Alizarin red staining was also carried out on 7 μm thick cross sections. After 10 min fixation by 10%
buffered formalin phosphate, the sections were washed 3x5 min with PBS and incubated with
alizarin red dye for 15 min at room temperature. After this procedure, the slides were washed in
ethanol 3 times and mounted by cytoseal 60 (Thermo Scientific).

Morphometric Central Nuclei Analysis
Three groups of mice, C57BL/Sn10J (control), and mdx randomized to either injection with PBS or
AAV9-μUtrophin, were studied by investigators blinded to specimen identification. Four to five
randomly chosen areas from each tibialis anterior, gastrocnemius, quadriceps, triceps, temporalis
and abdominal muscles muscle were stained with H&E and screened with light microscope for
quantification of centrally nucleated myofibers. Areas at the myotendinous junctions were excluded
from the measurements as they are rich in centrally nucleated fibers in both mdx and controls. In
total, 11,649 fibers were evaluated.

Immunofluorescence Staining Procedures
N-terminal and C-terminal Utrophin Double Stained sections from all muscle specimens were
processed for utrophin immunostaining by using both N-terminal polyclonal (against native and
recombinant utrophin) as well as C-terminal monoclonal (against native utrophin) antibodies. After
initial incubation for 20 mins in a 1% solution of Triton X-100 (Roche Diagnostics GmbH, Mannheim,
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Germany) diluted in 0.01M PBS (Roche Diagnostics GmbH, Mannheim, Germany), the specimens
were rinsed three times in PBS for 5 minutes each (3x5 mins). Sections were then incubated in 5%
normal donkey serum for 15 mins, followed by an incubation with N-terminal utrophin antibody (N19, sc-7460, goat polyclonal IgG, Santa Cruz, CA, USA, dilution 1:50) for 60 min at 37C. After a
second cycle 3x5 min PBS wash, the slides were incubated with 5% normal donkey serum for 15
mins in room temperature. The prepared sections were then incubated in donkey anti-goat IgGFITC (sc-2024, Santa Cruz, CA, USA, dilution 1:300) for 30 min at 37C. Following a third PBS
wash for 3x5 mins, the sections were first incubated with 10% normal goat serum (Invitrogen,
Scotland, UK) for 15 mins and then with the C-terminal utrophin antibody (MANCHO7, mouse
monoclonal IgG2a, Santa Cruz, CA, USA, dilution 1:25) at 37*C for 60 mins. After a PBS wash for
3x5 mins and incubation with 10% normal goat serum, the sections were incubated in goat antimouse IgG2a-Alexa Fluor594 (A-21140, Life Technologies, USA, dilution 1:300) for 30 min at 37*C.
The sections were again washed in PBS for 3x5 mins and mounted in Vectashield Mounting
Medium (H-1000) (Vector Laboratories, CA, USA) or Mounting Medium with DAPI (H-1500) (Vector
Laboratories. Photographs were taken with Leica DM6000B microscope (Leica, Germany).

Double

Immunofluorescence

Staining

for

γ-sarcoglycan/Laminin,

and

MyHC-

embryonic/Laminin, MYH16
The staining procedures for these proteins followed the same protocol as described previously 49.
Rabbit anti- γ-sarcoglycan (NBP1-59744, Novus Biologicals, Littleton, CO), polyclonal antibodies
were used at a dilution of 1:50 in PBS with Bovine Serum Albumin (BSA). MyHC-embryonic
monoclonal antibody (F1.652) (Developmental studies, Hybridoma Bank, Iowa, USA) was used at
a dilution of 1:50-1:100 in PBS.

Laminin chicken polyclonal antibody (ab14055-50, Abcam,

Cambridge, MA, USA) at a dilution of 1:500-1:1000 together with second goat anti-chicken IgY (TR)
antibody (ab7116, Abcam, Cambridge, MA, USA, dilution 1:300) were applied to identify muscle
fibers. MYH16 rabbit polyclonal antibody peptide sequence was generated using the human and
canine sequence of MYH16's "Loop 2" region. Validated by demonstrating sensitive and completely
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specific binding to the dominant myosin isoform expressed in the canine temporalis. Peptide
sequence: LLALLFKEEEAPAGS

Serum Creatine Kinase (CK) Assay
Blood serum was collected via venipuncture of the submandibular vein using a 5mm animal lancet
(Goldenrod Animal Lancet, Braintree Scientific, Inc, Braintree, MA). Total of 150μL were collected
in a heparinized blood collection tube (Terumo, Catalog Number: TMLH). The mice were carefully
monitored for 30 minutes post blood withdraw to observe for potential signs of distress. CK levels
were determined by the Clinical Pathology Laboratory at the Matthew J. Ryan Veterinary Hospital
of The University of Pennsylvania.

Ex-vivo evaluation of EDL muscle contractile properties
Ex-vivo assessment was performed by the Muscle Physiology Assessment Core of The University
of Pennsylvania. The physiological properties, including isometric twitch force, isometric tetanic
force, and force drop after ECCs, were quantified on freshly isolated EDL muscles from 2-monthold mdx mice using an Aurora Mouse 1200A System equipped with Dynamic Muscle Control v.5.3
software (50. All of these mice had undergone in-vivo force grip testing 24 hours prior to euthanasia
and ex-vivo testing. EDL muscles were maintained in continuously oxygenated Ringer's solution
(100 mM NaCl, 4.7 mM KCl, 3.4 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES and
5.5 mM D-glucose) at 24°C. The twitch stimulation protocol applied was a single stimulus with a
duration of 0.2 msec. For measuring tetanic maximal force generation, the same stimulus was
repeated at a frequency of 120 Hz for 500 msec. Five min were allowed between two tetanic
contractions to ensure muscle recovery. Muscle length was adjusted to obtain the maximal twitch
response. This length was measured between the outermost visible tips of the myotendinous
junctions and recorded as optimal length (L0). After testing the isometric properties of EDL, a series
of six eccentric contractions (ECCs – one every five minutes) was applied in cycles beginning with
repeated 500 ms isometric contractions followed by stretching the muscle by 10% of L0 over a final
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200 msec, while administering a maximal tetanic stimulation. The reported absolute force for each
ECC corresponds to the peak force during the isometric phase of the ECC.

Running wheel and Downhill Treadmill
To reduce chances of bias and to ensure the consistency and robustness of the blinded
experiments we used IACUC approved protocols as described (Song, Y. et al, 2017). Voluntary
running wheel distances were measured over 24 hours.

Baseline vertical activities were

determined for five minutes, followed by three minutes of rest in the original cages. An axial force
transducer was used to measure force. Downhill running distances were measured at +15o incline
with treadmill speed increasing from 10M/min (10 min), 11M/min (1 min), and then 12 M/min (6
min). Cessation was defined as either three consecutive shocks or the end of the protocol at 17
minutes.

Canine Model
Two groups of Golden Retriever Muscular Dystrophy (GRMD) dog models were used for these
experiments. The first group was bred in a colony at the A&M University and whelped at the
University of Pennsylvania. This study involved five affected GRMD dogs and four age matched
littermates including one wild type and three carrier females that served as a control group. All
dystrophic dogs were identified by elevated serum CPK levels and genotyped by PCR assay. All
pups were randomly assigned to treatment groups, and the investigators were kept blinded during
clinical and histological assessment. The pups were injected with AAV9 μUtrophin at 6-10 days of
age at the dose of 1.0x1013 vg/kg and 3.16x1013 vg/kg via external jugular vein approach. Two
pups were injected with low dose AAV9 μUtrophin, two were injected with high dose, and the
remaining one was injected with saline only. Each dog was weighed daily for the first 6 weeks and
weekly thereafter.

The second canine group involved two GRMD dogs at the age of approximately 7.5 weeks. Three
days prior to vector administration, the dogs were placed on oral prednisone 1mg/kg regimen for
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25 days. AAV9 μUtrophin was injected using the same approach at two different single doses of
1.25x1014vg/kg and 5.0x1013vg/kg respectively. The dogs were randomly assigned to dose and
the investigators were kept blinded during the clinical and histological assessments.

Deletional-null German Shorthaired pointer (GSHPMD) dogs were bred and housed in Texas A&M
University. Two seven-year-old affected GSHPMD dogs, Ned and Grinch, weighed 21kg and
24.2kg respectively, each dog received five intramuscular injections of AAV9-μDystrophin (Right)
and AAV9-μUtrophin (Left), with a total equivalent dose of 1x1012 vg/kg, into their tibialis anterior
compartment. All five Injection sites were tattooed, allowing us to pinpoint the injection sites for
muscle biopsies 4 weeks post-injection. Peripheral blood was collected pre-, 2, 4, 6, 8 weeks postinjection in order to collect Peripheral blood mononuclear cells (PBMCs).

Canine Tissue Procurement and Storage
The first group of GRMD dogs underwent needle biopsy of the cranial sartorius, vastus lateralis,
and triceps brachii muscles at approximately 6 weeks post vector injection. The specimens were
stored with a set of blinding codes to prevent bias during analysis and interpretation. Biopsies were
obtained through a spring loaded 14-gauge needle trocar, thereby significantly minimizing the postprocedural pain in the animals. Muscles biopsies were then snap-frozen in liquid nitrogen-cooled
isopentane, embedded in OCT medium (Sakuru, USA) and stored at -80 °C. Blinding codes were
broken after tissue analysis by individuals not associated with authorship of this study. One month
after vector exposure the second group of injected dogs underwent open muscle biopsy of the
same muscles. Seven weeks post vector administration these dogs were euthanized, and the
harvested tissue was cryopreserved in the same way.

Canine Histological Analysis
Transversely cut 7 μm serial sections were used for bright-field microscopy analysis and
immunofluorescence (IF) staining to examine μUtrophin expression and dystrophin-associated
glycoprotein complex (DGC) rescue. Muscle sections were stained with H&E for bright-field
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microscopy and mounted with permount. For IF staining, sections were blocked in 5% donkey
serum in PBS for 45 mins followed by incubation for 60 min at 37oC using a 1:350 dilution of
polyclonal goat anti-utrophin antibody (N-19, sc-7460, Santa Cruz, USA) and 1:250 dilution of
monoclonal γ-sarcoglycan antibody (ab55683, Abcam, USA). The sections were then rinsed three
times in PBS and incubated for 45 mins in Alexa488 donkey anti-goat secondary antibody or
Alexa540 donkey anti-mouse secondary antibody at a dilution of 1:1000. The slides were washed
twice with PBS for 5 mins followed by single wash of water and mounted with fade resistant
mounting media containing DAPI (H-1500, Vector Labs). Images were captured at the same setting
and processed via identical way by setting the limits and gain throughout to avoid any disparity in
IF images using an Olympus B-65 fluorescent microscope. Minimal Feret’s diameter and the
coefficients of variance were calculated according to TREAT-NMD protocol DMD_M.1.2.001 as
updated 1/28/2014.

Immunoblot Analysis
Immunoblot analysis was carried out by loading 20-40 μg/lane of whole cell or whole muscle lysate
on 10% sodium dodecyl sulfate-polyacrylamide gel. Protein was transferred to a polyvinylidene
difluoride membrane. µUtrophin was detected by a goat polyclonal antibody against the N-terminal
epitope at 1:500 dilution (N-19, sc-7460, Santa Cruz, USA) and a secondary antibody, a donkey
anti-goat antibody conjugated with horseradish peroxidase (Sigma-Aldrich) at 1:5000 dilution.
Protein detection and quantification was performed using the Odyssey infrared imaging system (LICOR). γ-sarcoglycan was detected by a mouse monoclonal antibody (Vector Labs VP-G803) and
a donkey, anti-mouse HRP conjugated secondary antibody (Santa Cruz Biotechnology).

Detection of Neutralizing anti-AAV Antibodies
To assess the humoral immune response against AAV 9 capsid proteins, blood sera were collected
at the day of birth, then at weeks 4 and 8 via peripheral vein. HEK 293 cells were seeded in a 48well plate at a density of 105 cells/well in 200 μl DMEM containing 10% fetal bovine serum. The
cells were cultured for 3–4 hours at 37 °C and allowed to adhere to the well. AAV9- Green
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Fluorescence Protein (GFP) vector (1 × 108 particles) was incubated with mice sera at serial
dilution with PBS for two hours at 4°C in a total volume of 25 μL. The mixture was then added to
cells in a final volume of 200μl which contained 4 × 106 particles of AAV9 and incubated for 24 or
48 hours at 37°C. Cells expressing GFP were counted under a fluorescent microscope. The
neutralizing antibody titer was calculated using the highest dilution where the percentage of GFPpositive cells was 50% less than control without sera.

Evaluation of cellular immune responses to AAV capsid, µUtrophin, and µDystrophin
Derived Peptides
Cellular immune responses against AAV9 capsid, µDystrophin, and µUtrophin antigens were
evaluated with an IFN-γ ELISpot assay (Mingozzi, F. et al. 2009). Peptide library spanning AAV9
VP1 capsid consists of pools A-C (20 amino acids in length, overlapping by 10 residues),
µDystrophin consists of pools A-D (15 amino acids in length, overlapping by 10 residues), and
µUtrophin consists of pools E-J (15 amino acids in length, overlapping by 10 residues). 96 well
High Protein Binding Immobilon-P membrane was incubated overnight with Canine IFN-gamma
monoclonal antibody. Peripheral blood mononuclear cells (PBMC) were isolated on Ficoll hypaque
gradients and cultured with wither synthetic peptides, PMA/Ionomyocin, or just media at 37°C, 5%
CO2 for 36 hours. One-hour incubation with Canine IFN-gamma Biotinylated monoclonal antibody
for one-hour. Responses were considered positive when Spot Forming Units (SFU) exceeded 50
in duplicate wells.

Statistical Analysis
Informative group sizes for AAV vector injections in mdx mice were estimated based on one of the
most sensitive and widely used histological assays available: the proportion of centrally nucleated
muscle fibers from mice necropsied at 8 weeks of age. To maximize the statistical power for the
number of animals used, we adopted the approach described by Aarts, et al. 2014, to
accommodate dependency among the multiple high- powered fields (HPFs) within a mouse. Mixed
effects models accounting for clustering within mouse, using an exchangeable correlation structure,
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were used to compare the three groups defined by genotype and treatment.

Estimation of the

intracluster correlation (ICC) from these models indicated a low value (<10%), suggesting a
relatively high effective sample size despite the necessarily small numbers of mice per group (at
least four). Other random-effects parameters calculated in this analysis include: the variance
between clusters, σ2u; the variance within clusters, σ2e; and the effective sample size, neff. To
characterize the distribution of minimum Feret diameter in wild type, treated, and untreated
dystrophic dogs, dots representing individual measurements from representative HPFs were
plotted. Due to the small number of dogs, this analysis is entirely descriptive. All analysis except
the proportion of centrally nucleated muscle fibers were presented as mean ± S.D. Statistical
analysis was processed using Prism 7 software (GraphPad). Statistical significance of p values is
indicated in the figures: *p < 0.05; **p< 0.001; ***p< 0.0001; n.s., not significant
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CONCLUSIONS AND FUTURE DIRECTIONS

This collection of work makes a significant contribution to the enormous amount of progress that
has been made over the last three decades to develop a gene replacement therapy for DMD. It
emphasizes the immune system’s power to distinguish self vs non-self-epitopes and highlights how
the predictive power of an animal model can rely on its genetic makeup. Experiments were
designed to inform an Investigational New Drug (IND) application, while providing an opportunity
for a mechanistic dissection. A common constraint of gene therapy for DMD is the deletional nature
of the protein deficiency in most patients, with the potential for recombinant dystrophin as a ‘nonself ’ protein to trigger autoimmune myositis. As an alternative we relied on a detailed analysis of
the molecular evolution of dystrophin and utrophin to inform a synthetic approach that maximizes
functionality while minimizing immunogenicity.

In neonatal mdx mice, we show complete recovery of peripheral myofiber nucleation and dramatic
prevention of disease pathophysiology following a single intraperitoneal injection of AAV-μUtrophin.
We attribute this finding to the combination of aggressive transgene optimization and early neonatal
administration using a high, but well tolerated vector dose. Neither before the functional efficacy
nor immunogenicity of a utrophin based gene therapy approach has never been tested in a large
animal model. In neonatal and juvenile GRMD dogs, where disease progression better
approximates that of DMD, we show that AAV-μUtrophin prevented histological signs of muscular
dystrophy, greatly reduced serum CK levels without any signs of toxicity. As more patients survive
to the third and fourth decade of their life due to advancements in technology, cardiomyopathy has
become a more prominent issue. Although significant levels of µUtrophin were detected in the
hearts of both mdx mice and GRMD dogs following systemic delivery, functional benefit in the heart
was not assessed and should be included in future experiments. Meanwhile, in the adult GSHPMD
deletional-null canine model, μUtrophin was protected by central tolerance, whereas μDystrophin
elicited a strong T cell mediated immune response against transduced myofibers.
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Based on our mouse and canine studies, systemic delivery of AAV-μUtrophin will require a dose
of at least 1 x 1014 vg/kg per DMD subject, which will create a significant burden for the
production and purification of good manufacturing practice grade vectors for trials and future
commercialization, thus increasing the price tag of the drug. In addition, higher doses raise safety
concerns of immune responses as indicated by several preclinical and clinical studies (Hinderer
2018) (Hordeaux et. al, 2018) (Morales et. al, 2020). In order to minimize toxicity, it can be
worthwhile to explore alternative AAV’s with the highest ratio of muscle to liver transduction
efficiency, like the recently characterized AAVMYO (Weinmann et. al 2020). Another area that
has room for improvement are the regulatory elements used to drive μUtrophin expression. Fiber
type preference has been noted in some promoters (Salva et. al, 2007) (Wang et al, 2008), so
making sure therapeutic levels of expression are reached in all affected fiber types will be
important. Leaky expression in antigen presenting cells is a major concern for any promoter
including CMV. To minimize toxicity from unwanted expression other groups have relied on the
use of muscle-specific promoters. Future experiments may involve evaluating alternative
promoters with increased specificity or additional regulatable elements.

Favorable results from a systemic gene therapy approach for treatment of spinal muscular atrophy
1 (SMA-1) at a high dose of 2x1014 vg/kg (AAV9-SMA1) suggests that this approach can be
tolerated, safe and effective for treating a neuromuscular disease (Mendell et al. 2017)
(NCT02122952). High-dose systemic AAV delivery has also been used to treat hemophilia A at
6.0x1013 vg/kg using an AAV5 vector with no serious SAEs (Rangarajan et. al, 2017). Meanwhile,
in the Audentes Therapeutics ASPIRO gene therapy trial for the treatment of X-linked myotubular
myopathy (XLMTM) revealed a spectacular therapeutic response at the low dose of 1 x 1014 vg/kg
(AAV8-MTM1) (NCT03199469). However, the tragic death of three subjects at the high dose of 3
x 1014 vg/kg were reported following a similar clinical course of progressive liver dysfunction and
sepsis several weeks post infusion. It’s worth noting that a significant proportion of XLMTM subjects
have underlying liver disease, a phenotype not observed in the XLMTM canine model, thus
highlighting the importance of using models that better replicate the disease state in order to more
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reliably predict outcomes. The ASPIRO trial was designed to mitigate this risk by excluding subjects
with “clinically significant underlying liver disease” yet four of the first six patients enrolled were
cited as having previous histories of hepatobiliary disease. Both the timing and nature of the SAEs
is consistent with a role for adaptive immune responses. A plausible mechanism for lethal sepsis
may have involved a cytotoxic cell mediated immune response against the transgene product, in
an already compromised liver. In Morales et. al, 2020, we highlight some of the lessons learned,
provide a path moving forward, while offering a unique patient perspective.

For accelerated subject recruitment in clinical trials, a major advantage of a μUtrophin-based
approach is that it is “agnostic” with regard to the underlying dystrophin mutation in a DMD subject.
In addition, because utrophin and dystrophin can be co-localized at the membrane, individuals with
BMD could also benefit. Our findings are also timely, given the multiple life-threatening SAEs
recently reported by sponsors systemically delivering micro versions of dystrophin (Chan et al
2020). These findings provide an immediate alternative to dystrophin-based gene therapies and
therefore may refocus the field towards the use of a functionally optimized, non-immunogenic
utrophin-based gene therapy approach for DMD. Taken together, these findings offer the unique
combination of both EFFICACY and SAFETY needed for clinical translation.
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ONGOING WORK

Fragment study and nanoUtrophin
Important to the understanding of dystrophin’s physiological role has been the characterization of
the pathogenesis that occurs shortly after acute muscle injury in mdx mice. Based on dystrophin’s
homology to spectrin and the absence of a detailed crystal structure, it has been loosely suggested
that the 24 spectrin-like triple helical repeats of the rod serve as a “shock absorber” that prevents
membrane disruption during force transduction as individual repeats unfold (Ortiz et al. 2005) (
Batchelor, C.L. et al. 2006). In a spectrin-based model, the lower degree of intermolecular forces
between triple helical repeats allows for less restrictive unfolding. However, a closer look of
dystrophin’s conserved phasing at each spectrin-like repeat, suggests that the rod domain more
closely resembles the spectroplakin relative, MACF1 (Figure 23A), whose spectrin-like repeats
contain a higher degree of interaction between residues, thus restricting the unfolding between
triple helical repeats (Figure 23B). A MACF1-based model challenges this interpretation of shock
absorption and suggests instead that dystrophin serves primarily as a stiff, loadbearing connecting
rod that does not unfold between contractions. Indeed, detailed crystal structures have been
determined for the first triple helical repeat of the rod domain (Muthu, M. et al. 2012), suggesting
the potential for greater inter-spectrin-like repeat interaction between residues. In other words, the
rod domain of spectrin is pliable like the “beads on a string” model, while dystrophin is stronger yet
more rigid like an “interlocking chain” (Figure 23C). This architecture may ultimately shift the
paradigm for modeling the mechanobiology of dystrophin/utrophin and also suggests that truncated
constructs could be made more durable.

The strong rationale for translation presented in Chapters 2-4 prompted follow up studies to
characterize the durability of μUtrophin. In these studies, we came across an unexpected
observation of a detectable fragment around the 75kDA molecular weight marker (Figure 24A). At
first glance it appeared to be a nonspecific band being picked up by the N-termini antibody, however
it failed to appear in either C57 or mdx non-treated animals, suggesting it was unique to μUtrophin
treated mdx mice. The design of μUtrophin involved an internal deletion in the wild type utrophin
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sequence that juxtaposes an N-terminal 79 kDa sub fragment to a 56 kDa C-terminal sub fragment.
Further proteomic characterization using immunoaffinity purification and liquid chromatography
with tandem mass spectrometry (Figure 24B) provided evidence that this ~79 kDa sub fragment
indeed matched the sequence of μUtrophin’s N-termini. This result suggests that there may be a
site-specific cleavage of a covalent bond at the internal deletion site. Based on the working theory
that full length dystrophin/utrophin transmits forces along the long axis of the rod domain, two
attractive hypotheses have emerged: The internally deleted junction found in recombinant
μUtrophin introduces a mechanical weakest link, thus exposing a 1) new proteolytic cleavage site
or 2) a load dependent covalent bond cleavage.

In BMD, several groups independently noted similar cleavage of a covalent bond in Becker-like
dystrophins at the deletion junctions (Beggs et al. 1992). Heart failure requiring transplantation in
BMD highlights the functional deficit that can persist with expression of in frame dystrophin with
small internal deletions or duplications. This hypothesis offers an immediate explanation for the
pathogenesis of BMD and the incomplete phenotypic reversal with the first generation AAV-sized
transgene products. Indeed, all groups currently in clinical trials using truncated dystrophin
constructs involve a single (Pfizer and Sarepta) or a double (Solid) splice within dystrophin’s rod
domain (Figure 2). Further understanding the mechanistic source of this sub-fragment can help us
develop the next generation of transgenes encoding stronger rod domains on the basis of threedimensional structural modeling.

A pair of tryptophan residues are the most conserved in the consensus sequence for the triple
helical repeat shared by dystrophin, utrophin, and the spectroplakins. The sequence divergence at
all other positions displays extensive evolutionary coupling, establishing that these regions of
individual repeats are not interchangeable from one repeat to another without destabilizing the
junctions between triple helices. As an initial test we designed and synthesized a novel transgene
encoding a hybrid triple helix composed of three splice sites (nanoUtrophin) without juxtaposing
incompatible triple helical repeats in order to minimize destabilization (Figure 25).
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We then conducted a blinded experiment in which mdx mice were randomized to receive humanbased transgenes encoding either μUtrophin or nanoUtrophin. Via immunofluorescence, both
recombinant proteins were properly localized to the sarcolemma and detected via Western Blot in
muscles of mdx mice (Figure 26 A, B). However, immunoblots showed that μUtrophin was cleaved
precisely at the end of the 79 kDa N-terminal sub fragment, while there was no detectable cleavage
of the nano-utrophin under similar physiological loading (Figure 26C). This suggests that the
superior strength of nanoUtrophin compared to μUtrophin will more closely approximate the
mechanobiology of full-length dystrophin and therefore provide further durability. nanoutrophin is
uniquely resistant to covalent bond cleavage under acute mechanical strain, suggesting that they
might provide superior protection of dystrophin-deficient striated muscles throughout the natural
duty cycle encountered in long-term physiological loading. Future experiments using AAVnanoUtrophin treated mdx mice will involve a similar standard set by our AAV-μUtrophin treated
mdx mice described in Chapter 2. Sustained histological protection against all signs of muscular
dystrophy, the normalization of serum CK, along with a suite of integrative physiological functional
assays.

In order to rule out if site-specific cleavage was due to proteolysis as a result of improper tissue
handling, tissue lysates from nanoUtrophin and μUtrophin injected mice were incubate at 37* for
either 0, 5, 30, and 60 minutes in the absence of protease inhibitors. The idea behind these
conditions was to create an environment that facilitated the cleavage of any exposed vulnerable
sites by endogenous proteases. Subsequent immunoblot analysis showed no increase in detection
of the ~79kDA sub-fragment at any of the time points (Figure 27A). These results suggest that
improper tissue handling post dissection is not likely to be responsible for the presence of the
~79kDA sub-fragment but does not rule out potential proteolytic cleavage in-situ.

In an attempt to further understand the role of endogenous proteases we generated an ex-vivo
assay where a mouse hemi-carcass was submerged in physiological solution. Both AAVnanoUtrophin and AAV-μUtrophin injected underwent a series of electrical field stimulations with
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the goal of achieving body-wide forceful contraction. Western blot analysis of tissue processed in
the presence of protease inhibitors once again showed the presence of a ~79kDA sub-fragment.
However, there was no significant difference between stimulated or non-stimulated tissue (Figure
27B). Upon revisiting the feasibility of this ex-vivo assay, it became apparent that the magnitude of
forceful contraction being generated was sub-maximal and greatly depended on the diffusion of
solutes into the hemi-carcass.

We then created a novel in-vivo injury assay, where all the muscles are expected to be perfused
by the animal’s vasculature and therefore should provide an opportunity for muscles to generate
maximal contractions. Treated and non-treated mdx mice were anesthetized and a bolus of Evans
Blue dye (EBD) was administered systemically via a retro-orbital injection. Once the animal became
visibly blue, the sciatic nerve was micro surgically exposed and stimulated to activate unilateral
lengthening contractures (LC) with the goal of inducing acute injury. Untreated mdx mice
undergoing unilateral LC showed rapidly evolving signs of injury. Harvested lower limb muscles
(Tibialis Anterior, Gastrocnemius, Quadriceps, and Hamstrings) were visibly blue immediately after
stimulation (Figure 28A). This suggests that the dye entered the recently compromised myofibers.
Gastrocnemius muscles were excised and frozen two hours post-LC. Visualization of sectioned
fibers showed strong EBD staining on only the LC side (Figure 28B). Western blots of AAVμUtrophin treated mdx GM’s subjected to the same stimulus stained positive for the ~79 kDa
fragment, unlike their contralateral control (C) side (Figure 28C). Interestingly, abdominal walls of
AAV-μUtrophin mdx mice showed variable EBD staining. However, there was a strong correlation
for the presence of a ~79 kDA sub-fragment in only the EBD (+) when compared to the EBD (-)
tissue (Figure 28D). The interpretation of these results along with data from BMD patients (Beggs
et al. 1992) suggests a mechanism that involves a load-dependent covalent bond cleavage,
perhaps through localized unfolding and proteolysis, at the weakest link created by juxtaposing
spectrin repeats that haven’t evolved side by side.
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Figure 23. Modeling of spectrin triple helical repeat A, Human beta heavy
spectrin, dystrophin, and MACF1 depicted with the rod domains vertically aligned
to a consensus sequence for the triple helical domain HMM. Superimposed are
the positions and phases of introns relative to the corresponding coding
sequences. B, Three-dimensional depiction of adjacent spectrin-like repeats (SR)
22 and 23 for Spectrin (left) and MACF1 (right). C, The rod domain of Spectrin is
pliable like the “beads on a string” model, while Dystrophin is stronger yet more
rigid like an “interlocking chain”.
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Figure 24. Characterization of μUtrophin’s sub-fragment. A, 79 kDa band is
detected in load-bearing muscles of AAV-μUtrophin injected mdx mice. Lanes 1,
2, and 4: non-load-bearing flexor muscles; 3, 5, and 7: load-bearing extensor
muscles; 6 liver; 8 PBS; 9 molecular weight. B, Further proteomic characterization
using immunoaffinity purification and liquid chromatography with tandem mass
spectrometry confirms that the sequence of the 79 kDa fragment matches the Nterminal sequence of μUtrophin.
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Figure 25. Highly conserved tryptophan residues of the spectrin-like repeat
HMM logo. The tryptophans depicted in yellow are the most conserved residues
in the HMM for triple helical repeat domains in dystrophin, utrophin, and the
spectroplakins. The conservation of tryptophan residues provides a guidepost for
us to create a hybrid triple splice across the helical repeat.
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Figure 26. Systemic administration of nanoUtrophin in mdx mice results in
proper localization, expression, and resistance to cleavage. A,
Immunofluorescence staining of representative limb muscles, Gastrocnemius
(GM) and Tibialis Anterior (TA), show proper localized expression of nanoUtrophin
at the sarcolemma. B, Western Blot shows broad biodistribution of nanoUtrophin
in TA, Heart, Triceps, Diaphragm, and Quadriceps. C, Under similar physiological
loading in-vivo, western blot analysis shows that in load bearing muscles
(Quadriceps/Triceps) there is a 79 kd N-terminal sub fragment in only μUtrophin
and not nanoUtrophin treated mdx mice.
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Figure 27. Hemi carcass field stimulation and endogenous proteases fail to
cleave nanoUtrophin or μUtrophin. A, Western blot analysis from AAVμUtrophin injected mdx mice hemi carcass post (+/-) field stimulation. B, Both
nanoUtrophin and μUtrophin injected tissue lysates were allowed to incubate at
37* for 0, 5, 30, and 60 minutes in the absence of protease inhibitors.
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Figure 28. Characterization of a novel in-vivo lower limb injurious assay in
mdx mice with the use of Evans Blue Dye. A, Surgically exposed sciatic nerve
underwent a series of 50 electrically stimulated lengthening contractures. Evans
blue dye (EBD) was systemically administered before injury protocol and allowed
to circulate. 2hours post injury protocol, tissue harvest of relevant stimulated and
non-stimulated muscles. B, Immunofluorescence staining of sectioned
gastrocnemius with Wheat Germ Agglutinin (WGA-green) and autofluorescence of
EBD via red channel, reveals a disproportionate amount of positive EBD staining
on only the lengthening contracted (LC) and none on the control © side. C,
Subsequent western blot analysis confirms the presence of a 79kD fragment on
only the LC side. D, Western blot of AAV-μUtrophin mdx mice showed the more
pronounced presence of a ~79kDA sub-fragment in visibly EBD (+) regions of
abdominal walls.
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Development of prospective AAV-based SARS-CoV-2 vaccine

Our findings described in Chapters 2-4 were published in October 2019 (Song, Morales, Malik et
al 2019). By December, the city of Wuhan in China had become the epicenter for an outbreak of
the novel coronavirus, SARS-CoV-2, the agent responsible for COVID-19 disease. By March 11,
2020 the World Health Organization declared COVID-19 a global pandemic. As of December 2020,
there are over 60 million global cases, 1.5 million deaths (GISAID. 2020), with many countries
experiencing 2nd waves. As labs around the world began to scramble to gain a better understanding
of SARS-CoV-2, our lab initiated a parallel study that hinged on the immunological findings from
our Muscular Dystrophy studies. Specifically, we were intrigued by our findings in the deletionalnull GSHPMD canine model, where an intramuscular injection of AAV-μDystrophin elicited a
powerful immune response against “non-self” epitopes, thus highlighting the importance of central
tolerance (Figure 22). Essentially these animals had been vaccinated against dystrophin. The
question then became, how can we take our hypothesis of self vs non-self, one step further and
explore its potential use as a vaccine platform.

Here we describe the design and initial pre-clinical testing for a potential AAV-based vaccine
against SARS-CoV-2. The two major protein structures found in SARS-CoV-2 that can be
recognized as a foreign antigen are the Nucleocapsid and Spike (Figure 29A), which therefore
makes them key targets for vaccines. The Nucleocapsid protein encloses the RNA based genome,
while the Spike protein is the major surface antigen used to gain access into host epithelial cells by
engaging the angiotensin-converting enzyme 2 (ACE2) receptor (Wrapp et al. 2020). The
nucleocapsid at 1257bp (Kang et al. 2020) can easily be made to fit into an AAV vector. Meanwhile
the Spike protein is too large at 3819bp and therefore was strategically truncated with an emphasis
on mutagenizing epitopes known to exacerbate COVID-19 through an antibody dependent
enhancement (ADE) process (Lee et al. 2020).

A synthetic truncated Spike transgene (M8B) was generated by introducing a total of 8 mutations
(Figure 29C, D). 1) At the extreme C-terminus, 19 amino acids were removed based on the
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assumption that in the absence of this sequence, viral proteins are able to be trafficked to the
membrane (Sadasivan, Singh et al. 2017), where immune recognition takes place. In addition, a
flag tag was introduced at the C-terminus for facilitated detection. 2) Two Prolines were introduced
in order to trap the Spike protein in its activated pre-fusion state. The introduction of these two
Prolines has been a tool frequently used by structural biologist to capture type 1 envelope viral
proteins like SARS-CoV-2, in their pre-fusion state (Wrapp, Wang et al. 2020). Protease sites were
eliminated in the 3) Spike protein S1/S2 junction and 4) S2’ region. Removal of both protease sites
are also important for capturing the Spike protein in its pre-fusion state (Simmons, Gosalia et al.
2005) (Belouzard, Chu et al. 2009). 6) The single best characterized 6 AA ADE epitope in SARSCoV-1 is 100% conserved with SAR-CoV-2 (Wang et al. 2016.) and so we decided to substitute
this epitope with a Middle East Respiratory Syndrome (MERS) virus equivalent sequence, with the
goal of minimizing the risk of destabilizing the region. This decision would later be reinforced by the
recent observation of a newly derived substitution in the sequence of SARS-CoV-2 currently
circulating the human population (Yurkovetskiy, Wang et al. 2020). 7) At the N-terminus the first
deletion was designed to preserve a 20AA signaling sequence that enables the polypeptide to
direct the ribosome to the ER (Li, Moore et al. 2003). 8) Deletion of the NTD domain, which is highly
homologous to galectin, a lectin known to bind sugar groups of proteins, like the ones found on the
surface of cells. Lectin also plays a critical role in cell to cell interactions, which makes it likely that
a virus would incorporate such a sequence. There is no evidence that the NTD of SARS-CoV-1 or
2 binds to anything. An insertion of a glycine was introduced in the remainder of the polypeptide to
relief torsional strain and allow proper folding after removing the NTD domain.

In order to maximize expression, our synthetic M8B and Nucleocapsid transgene was cloned into
the exact vector that was used in our previous dystrophic studies, which relies on the constitutive
CMV promoter, all made to fit in an AAV9 vector (AAV-CMV5U-M8B) (Figure 29D). When
evaluating immunogenicity, we also thought it would be important to include mdx mice in our studies
because of the large literature that suggests that dystrophic muscle is under tightened immunesurveillance compared to normal muscle creating a heightened immune response.
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Meanwhile, splenocytes isolated at 25 days post injection showed a robust cell mediated immune
response against M8B (Figure 30). Remarkably, this simple substitution of “self” for a “non-self”
protein resulted in the rapid generation of abundant gamma-interferon secreting T cells targeting
epitopes throughout the primary structure of the spike protein. Other groups have reported how a
similar T cell response confers a survival benefit in challenging studies. Future directions will
involve assessing humoral immune responses as well as challenging studies using ACE2 receptor
transgenic mice (Yang et al. 2007).

Figure 29. Synthetic design of M8B Spike and Nucleocapsid construct. A,
Spike and Nucleocapsid are the two major protein structures found in SARS-CoV2. B, Nucleocapsid construct schematic flanked by adeno associated viral vector
Inverted Terminal Repeat sequence (ITR) and driven by a CMV promoter (AAVCMV-Nucleocapsid). Domains include N-terminal Domain (NTD), Serine/Arginine
(S/R) linker, C-terminal Domain (CTD) C, A total of 8 mutations and their relative
position along full length Spike schematic and its three dimensional crystal
structure. M8B construct is flanked by adeno associated viral vector Inverted
Terminal Repeat sequence (ITR) and driven by a CMV promoter (AAV-CMVMGB). Domains include N-terminal Domain (NTD), Receptor binding domain
(RBD), S1/S2 and S2’ protease sites, and transmembrane domain (TM).
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Figure 30: Cell mediated immune response via an ELISpot assay 25 days
post intramuscular expression of M8B and Nucleocapsid in adult mice.
Peripheral blood mononuclear cells (PBMCs) collected 25 days post-injection were
cultured with peptide pools spanning the Spike’s N termini (Pool 1) and C-termini
(Pool 2) as well as Nucleocapsid amino acid sequences, while phorbol myristate
acetate (PMA)/ionomycin serve as a positive control. A positive result is interpreted
as ≥5 spot forming units (SFU) per 1 x 105 PBMCs (dotted line).
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